1
|
Griffiths CA, Rees A, Morgan A, Korkees F. Optimisation of 3D Printing for Microcellular Polymers. Polymers (Basel) 2023; 15:3910. [PMID: 37835959 PMCID: PMC10575440 DOI: 10.3390/polym15193910] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Revised: 09/14/2023] [Accepted: 09/26/2023] [Indexed: 10/15/2023] Open
Abstract
Polymers are extensively used in various industries due to their versatility, durability and cost-effectiveness. To ensure functionality and longevity, polymer parts must have sufficient strength to endure external forces without deformation or breakage. Traditional approaches to increasing part strength involve adding more material; however, balancing strength to weight relationships is challenging. This paper explorers the viability of manufacturing lightweight components using a microcellular foaming polymer. Microcellular foaming has emerged as a helpful tool to achieve an optimal strength-to-weight ratio; offering advantages such as lightweight, improved mechanical properties, reduced material usage, better insulation and improved cost-effectiveness. It can also contribute to improved fuel efficiency and reduced carbon emissions, making them environmentally favourable. The combination of additive manufacturing (AM) and microcellular foaming has opened new possibilities for design innovation. This text highlights the challenges and efforts in incorporating foaming techniques into 3D printing processes, specifically fused filament fabrication (FFF). This study reveals that microcellular polymers are a viable option when balancing part strength and weight. The experiments completed during the formulation of this paper demonstrated that lightweight LW-PLA parts were significantly lighter than standard PLA parts and that a design of experiments approach can be used to optimise strength properties and provide insights into optimising manufacturability. Microcellular polymers present an opportunity for lighter and stronger 3D printed parts, offering potential energy and material savings for sustainable manufacturing practices.
Collapse
|
2
|
Chen J, Rees A, Coughlan CH, Goodison W, Murphy E, Chandratheva A. Ischaemic stroke with multi-focal venous and arterial thrombosis due to hyperhomocysteinemia: anabolic androgenic steroid use and MTHFR c.667 C > T variant - a case report. BMC Neurol 2023; 23:167. [PMID: 37101129 PMCID: PMC10131300 DOI: 10.1186/s12883-023-03197-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Accepted: 04/03/2023] [Indexed: 04/28/2023] Open
Abstract
BACKGROUND Severely elevated serum homocysteine is a rare cause of ischaemic stroke and extra-cranial arterial and venous thrombosis. Several factors can lead to mild elevation of homocysteine including dietary folate and B12 deficiency, and genetic variants of the methylenetetrahydrofolate reductase (MTHFR) enzyme. The use of Anabolic androgenic steroid (AAS) is under-reported, but increasingly linked to ischaemic stroke and can raise homocysteine levels. CASE REPORT We present a case of a man in his 40s with a large left middle cerebral artery (MCA) territory ischaemic stroke and combined multifocal, extracranial venous, and arterial thrombosis. His past medical history was significant for Crohn's disease and covert use of AAS. A young stroke screen was negative except for a severely elevated total homocysteine concentration, folate and B12 deficiencies. Further tests revealed he was homozygous for the methylenetetrahydrofolate reductase enzyme thermolabile variant (MTHFR c.667 C > T). The etiology of this stroke was a hypercoagulable state induced by raised plasma homocysteine. Raised homocysteine in this case was likely multifactorial and related to chronic AAS use in combination with the homozygous MTHFR c.677 C > T thermolabile variant, folate deficiency and, vitamin B12 deficiency. CONCLUSION In summary, hyperhomocysteinemia is an important potential cause of ischaemic stroke and may result from genetic, dietary, and social factors. Anabolic androgenic steroid use is an important risk factor for clinicians to consider, particularly in cases of young stroke with elevated serum homocysteine. Testing for MFTHR variants in stroke patients with raised homocysteine may be useful to guide secondary stroke prevention through adequate vitamin supplementation. Further studies looking into primary and secondary stroke prevention in the high-risk MTHFR variant cohort are necessary.
Collapse
Affiliation(s)
- Jpk Chen
- National Hospital for Neurology and Neurosurgery, London, UK.
| | - A Rees
- National Hospital for Neurology and Neurosurgery, London, UK
| | - C H Coughlan
- University College London Hospitals NHS Foundation Trust, London, UK
| | - W Goodison
- National Hospital for Neurology and Neurosurgery, London, UK
| | - E Murphy
- University College London Hospitals NHS Foundation Trust, London, UK
| | - A Chandratheva
- University College London Hospitals NHS Foundation Trust, London, UK
| |
Collapse
|
3
|
Harding OJ, Griffiths CA, Rees A, Pletsas D. Methods to Reduce Energy and Polymer Consumption for Fused Filament Fabrication 3D Printing. Polymers (Basel) 2023; 15:polym15081874. [PMID: 37112021 PMCID: PMC10144130 DOI: 10.3390/polym15081874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Revised: 03/27/2023] [Accepted: 04/07/2023] [Indexed: 04/29/2023] Open
Abstract
Fused Filament Fabrication (FFF) 3D printing is an additive technology used to manufacture parts. Used in the engineering industry for prototyping polymetric parts, this disruptive technology has been adopted commercially and there are affordable printers on the market that allow for at-home printing. This paper examines six methods of reducing the energy and material consumption of 3D printing. Using different commercial printers, each approach was investigated experimentally, and the potential savings were quantified. The modification most effective at reducing energy consumption was the hot-end insulation, with savings of 33.8-30.63%, followed by the sealed enclosure, yielding an average power reduction of 18%. For material, the most influential change was noted using 'lightning infill', reducing material consumption by 51%. The methodology includes a combined energy- and material-saving approach in the production of a referenceable 'Utah Teapot' sample object. Using combined techniques on the Utah Teapot print, the material consumption was reduced by values between 55.8% and 56.4%, and power consumption was reduced by 29% to 38%. The implementation of a data-logging system allowed us to identify significant thermal management and material usage opportunities to minimise power consumption, providing solutions for a more positive impact on the sustainable manufacturing of 3D printed parts.
Collapse
Affiliation(s)
| | | | - Andrew Rees
- College of Engineering, Swansea University, Swansea SA2 8PP, UK
| | | |
Collapse
|
4
|
Denduluri SK, Rees A, Nord KM, Loeffler BJ, Gaston RG. The Starfish Procedure for Independent Digital Control of a Myoelectric Prosthesis. Tech Hand Up Extrem Surg 2023; 27:61-67. [PMID: 36189486 DOI: 10.1097/bth.0000000000000412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Management of partial hand amputations is a notable clinical challenge. Historically, myoelectric prostheses have not allowed for independent digital control, resulting in unsatisfactory function and high rejection rates among upper extremity amputees. The Starfish Procedure was developed for patients who sustained loss of multiple digits through the level of the base of the proximal phalanx or distal metacarpal. The procedure involves the pedicled transfer of 1 or more dorsal interosseous muscles to a subcutaneous location. This allows for a myoelectric sensor to capture the signals generated by these transferred muscles, thereby enabling intuitive, independent, digital prosthetic flexion and extension. In this article, we detail the relevant anatomy, indications, and technique for performing the Starfish Procedure. Given our patients' promising outcomes to date, we hope this technique paper will encourage upper extremity surgeons of all training backgrounds to perform this relatively straightforward procedure, thereby allowing patients with life-altering finger amputations to regain meaningful function by enhancing control of digital prostheses.
Collapse
Affiliation(s)
- Sahitya K Denduluri
- OrthoCarolina Hand Center and Atrium Musculoskeletal Institute, Charlotte, North Carolina, USA
| | | | | | | | | |
Collapse
|
5
|
Allon G, Lemaître S, Hay G, Rees A, Westcott M. Iris melanoma versus syphilitic iris nodule: A diagnostic challenge. J Fr Ophtalmol 2023; 46:e106-e107. [PMID: 36775730 DOI: 10.1016/j.jfo.2022.09.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2022] [Accepted: 09/12/2022] [Indexed: 02/12/2023]
Affiliation(s)
- G Allon
- Retina Service, Moorfields Eye Hospital, 162, City road, EC1V 2PD London, United Kingdom.
| | - S Lemaître
- Retina Service, Moorfields Eye Hospital, 162, City road, EC1V 2PD London, United Kingdom; Ocular oncology service, Moorfields Eye Hospital NHS Foundation Trust, 162, City road, EC1V 2PD London, United Kingdom
| | - G Hay
- Ocular oncology service, Moorfields Eye Hospital NHS Foundation Trust, 162, City road, EC1V 2PD London, United Kingdom
| | - A Rees
- Retina Service, Moorfields Eye Hospital, 162, City road, EC1V 2PD London, United Kingdom
| | - M Westcott
- Retina Service, Moorfields Eye Hospital, 162, City road, EC1V 2PD London, United Kingdom
| |
Collapse
|
6
|
Oszwald A, Mejía-Pedroza RA, Schachner H, Aigner C, Rees A, Kain R. Digital Spatial Profiling of Glomerular Gene Expression in Pauci-Immune Focal Necrotizing Glomerulonephritis. Kidney360 2023; 4:83-91. [PMID: 36700908 PMCID: PMC10101620 DOI: 10.34067/kid.000461202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Accepted: 11/09/2022] [Indexed: 01/27/2023]
Abstract
Pauci-immune focal necrotizing glomerulonephritis (piFNGN) involves asynchronous onset and progression of injurious lesions in biopsies. Pathologists can describe this heterogeneity within a biopsy, but translating the information into prognostic or expression analyses is challenging. Understanding the underlying molecular processes could improve treatment; however, bulk or single-cell transcriptomic analyses of dissociated tissue disregard the heterogeneity of glomerular injury. We characterize protein and mRNA expression of individual glomeruli in 20 biopsies from 18 patients with antineutrophil cytoplasmic antibody-associated piFNGN using the NanoString digital spatial profiling (DSP) platform. For this purpose, circular annotations of glomeruli were analyzed using protein, immuno-oncology RNA, and Cancer Transcriptome Atlas panels (n=120, 72, and 48 glomeruli, respectively). Histologic evaluation of glomerular patterns of injury was performed in adjacent serial sections. Expression data were processed by log2 transformation, quantile normalization, and batch adjustment. DSP revealed distinct but overlapping gene expression profiles relating to the morphological evolution of injurious lesions, including dynamic expression of various immune checkpoint regulators. Enrichment analysis indicated deregulated pathways that underline known and highlight novel potential mechanisms of disease. Moreover, by capturing individual glomeruli, DSP describes heterogeneity between and within biopsies. We demonstrate the benefit of spatial profiling for characterization of heterogeneous glomerular injury, indicating novel molecular correlates of glomerular injury in piFNGN.
Collapse
Affiliation(s)
- André Oszwald
- Department of Pathology, Medical University of Vienna, Vienna, Austria
| | | | - Helga Schachner
- Department of Pathology, Medical University of Vienna, Vienna, Austria
| | - Christof Aigner
- Internal Medicine III, Medical University of Vienna, Vienna, Austria
| | - Andrew Rees
- Department of Pathology, Medical University of Vienna, Vienna, Austria
| | - Renate Kain
- Department of Pathology, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
7
|
Picard M, Pochon X, Atalah J, Pearman JK, Rees A, Howarth JD, Moy CM, Vandergoes MJ, Hawes I, Khan S, Wood SA. Using metabarcoding and droplet digital PCR to investigate drivers of historical shifts in cyanobacteria from six contrasting lakes. Sci Rep 2022; 12:12810. [PMID: 35896561 PMCID: PMC9329365 DOI: 10.1038/s41598-022-14216-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2021] [Accepted: 06/02/2022] [Indexed: 11/16/2022] Open
Abstract
The frequency and intensity of cyanobacterial blooms is increasing worldwide. Multiple factors are implicated, most of which are anthropogenic. New Zealand provides a useful location to study the impacts of human settlement on lake ecosystems. The first humans (Polynesians) arrived about 750 years ago. Following their settlement, there were marked landscape modifications which intensified after European settlement about 150 years ago. The aims of this study were to reconstruct cyanobacterial communities in six lakes over the last 1000 years and explore key drivers of change. Cyanobacterial environmental DNA was extracted from sediment cores and analysed using metabarcoding and droplet digital PCR. Cyanobacteria, including potentially toxic or bloom forming species, were already present in these lakes prior to human arrival, however their overall abundance was low. Total cyanobacteria abundance and richness increased in all lakes after European settlement but was very pronounced in four lakes, where bloom-forming taxa became dominant. These shifts occurred concomitant with land-use change. The catchment of one deteriorated lake is only moderately modified, thus the introduction of non-native fish is posited as the key factor driving this change. The paleolimnological approach used in this study has enabled new insights into timing and potential causes of changes in cyanobacterial communities.
Collapse
Affiliation(s)
- Maïlys Picard
- Coastal and Freshwater Group, Cawthron Institute, 98 Halifax Street East, Nelson, 7010, New Zealand. .,Department of Biological Sciences, School of Biological Sciences, University of Waikato, Hamilton, 3216, New Zealand.
| | - Xavier Pochon
- Coastal and Freshwater Group, Cawthron Institute, 98 Halifax Street East, Nelson, 7010, New Zealand.,Institute of Marine Science, University of Auckland, Private Bag 349, Warkworth, 0941, New Zealand
| | - Javier Atalah
- Coastal and Freshwater Group, Cawthron Institute, 98 Halifax Street East, Nelson, 7010, New Zealand
| | - John K Pearman
- Coastal and Freshwater Group, Cawthron Institute, 98 Halifax Street East, Nelson, 7010, New Zealand
| | - Andrew Rees
- School of Geography, Environment and Earth Sciences, Victoria University of Wellington, PO Box 600, Wellington, New Zealand
| | - Jamie D Howarth
- School of Geography, Environment and Earth Sciences, Victoria University of Wellington, PO Box 600, Wellington, New Zealand
| | - Christopher M Moy
- Department of Zoology, University of Otago, 340 Great King Street, North Dunedin, Dunedin, 9016, New Zealand
| | | | - Ian Hawes
- Department of Biological Sciences, School of Biological Sciences, University of Waikato, Hamilton, 3216, New Zealand
| | - Samiullah Khan
- Department of Zoology, University of Otago, 340 Great King Street, North Dunedin, Dunedin, 9016, New Zealand
| | - Susanna A Wood
- Coastal and Freshwater Group, Cawthron Institute, 98 Halifax Street East, Nelson, 7010, New Zealand
| |
Collapse
|
8
|
Papanikolaou N, Coulden A, Parker N, Lee S, Kelly C, Anderson R, Rees A, Cox J, Dhillo W, Meeran K, Al-Memar M, Karavitaki N, Jayasena C. P-698 Pituitary functioning gonadotroph adenomas (FGA)-induced ovarian hyperstimulation syndrome (OHSS): results from tertiary neuroendocrine centres in the UK. Hum Reprod 2022. [DOI: 10.1093/humrep/deac107.647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
There are no published series of OHSS due to FGA. What FGA features should clinicians look for during OHSS, and what treatments are effective?
Summary answer
FGA tumour size is always >10mm. Other pituitary hormones may be deficient. Surgical resection of FGA is an effective treatment for OHSS.
What is known already
Pituitary adenomas affect 1:1000 adults and are classified as functioning or non-functioning. Non-functioning pituitary adenomas do not secrete hormones, but most commonly stain histologically gonadotroph cells. Functional pituitary adenomas secrete hormones such as prolactin causing prolactinoma. However, it is rare for a pituitary tumour to cause clinical features of excessive gonadotrophins (functioning gonadotroph adenoma; FGA).
Single case reports, but no case series, have been published on the presentation of FGA-induced OHSS in women.
Surgical excision of adenomas has been reported to cause remission of symptoms, though systematic data are lacking owing to rarity of these tumours.
Study design, size, duration
National case series from tertiary neuroendocrine units in England, Wales and Scotland.
Participants/materials, setting, methods
Eight high-volume pituitary endocrine tertiary units within England, Wales and Scotland audited their records for any cases of FGA-induced OHSS; only seven patients have been identified to date. In all cases, there had been no recent exposure to assisted reproductive technologies (ART) or drugs known to induce OHSS including gonadotrophins or selective oestrogen receptor modulators (SERMS).
Main results and the role of chance
Seven cases of FGA were identified with mean age 31.6 years (range 16-48) at diagnosis. Two-of-seven women presented acutely unwell with abdominal pain, distention and palpable mass requiring oophorectomy for ovarian torsion/ruptured ovarian cyst. The remaining five women presented with abdominal pain (n = 2), thyrotoxicosis (n = 1), menstrual irregularities/galactorrhoea (n = 1) and visual disturbances (n = 1). All women experienced intermittent pelvic pain during medical attendance. Pelvic ultrasound demonstrated enlarged multiseptated ovaries (volume ranging 27-442cm3). Ascites was noted in one woman. Six women had visual field defects due to optic chiasm compression on formal assessment. Median FSH was 26.10 u/L (8.3-33), but LH was <2.5 u/L in all cases. Estradiol (E2) far exceeded the reference range in 5/7 women (2990 to > 18000pmol/L);E2 was at the upper limit of normal in the remaining 2/7 women (960-1450pmol/L). Hyperprolactinaemia, hyperthyroidism and other pituitary hormones deficiency were noted in 6/7, 1/7 and 4/7 women respectively. All FGAs were macroadenomas with diameters ranging 16-48mm. Two patients were administered a somatostatin analogue prior to surgery, but FSH, E2 and tumour size did not change. Transsphenoidal surgery was performed in 6/7 women, and always improved symptomatic and biochemical features of OHSS; however, residual FGA tumour was present post-operatively in all cases studied.
Limitations, reasons for caution
It is possible that some ‘non-functioning’ gonadotroph adenomas cause subclinical problems including menstrual irregularity and mild OHSS which were never diagnosed.
We have insufficient data to determine the prognosis for future pregnancy after FGA-induced OHSS.
This study utilised historical case-notes, so some data is missing.
Wider implications of the findings
The ‘spontaneous’ presentation of OHSS may be confusing for clinicians. We report that FGA is an important cause of spontaneous OHSS which has well-defined biochemical and radiological characteristics, which may be treated effectively in the short-to-medium with pituitary surgery. Results of this study may provide greater awareness of FGA-induced OHSS.
Trial registration number
N/A
Collapse
Affiliation(s)
- N Papanikolaou
- Imperial College London, Metabolism-Digestion and Reproduction , London, United Kingdom
| | - A Coulden
- University hospitals Birmingham NHS Foundation Trust , Endocrinology, Birmingham, United Kingdom
| | - N Parker
- Imperial College Healthcare NHS Trust, Obstetrics and Gynaecology , London, United Kingdom
| | - S Lee
- Royal Infirmary of Edinburgh , Endocrinology, Edinburgh, United Kingdom
| | - C Kelly
- NHS Forth Valley , Endocrinology, Larbert, United Kingdom
| | - R Anderson
- University of Edinburgh, Obstetrics and Gynaecology- Center for Reproductive health , Edinburgh, United Kingdom
| | - A Rees
- Cardiff University- School of Medicine , Endocrinology, Cardiff, United Kingdom
| | - J Cox
- Imperial College Healthcare NHS Trust , Endocrinology, London, United Kingdom
| | - W Dhillo
- Imperial College London, Metabolism- Digestion and Reproduction , London, United Kingdom
| | - K Meeran
- Imperial College Healthcare NHS Trust , Endocrinology, London, United Kingdom
| | - M Al-Memar
- Imperial College Healthcare NHS Trust, Obstetrics and Gynaecology , London, United Kingdom
| | - N Karavitaki
- University hospitals Birmingham NHS Foundation Trust , Endocrinology, Birmingham, United Kingdom
| | - C Jayasena
- Imperial College London, Metabolism-Digestion and Reproduction , London, United Kingdom
| |
Collapse
|
9
|
Pearman JK, Biessy L, Howarth JD, Vandergoes MJ, Rees A, Wood SA. Deciphering the molecular signal from past and alive bacterial communities in aquatic sedimentary archives. Mol Ecol Resour 2021; 22:877-890. [PMID: 34562066 DOI: 10.1111/1755-0998.13515] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 09/01/2021] [Accepted: 09/22/2021] [Indexed: 01/04/2023]
Abstract
Lake sediments accumulate information on biological communities thus acting as natural archives. Traditionally paleolimnology has focussed on fossilized remains of organisms, however, many organisms do not leave fossil evidence, meaning major ecosystem components are missing from environmental reconstructions. Many paleolimnology studies now incorporate molecular methods, including investigating microbial communities using environmental DNA (eDNA), but there is uncertainty about the contribution of living organisms to molecular inventories. In the present study, we obtained DNA and RNA inventories from sediment spanning 700 years to investigate the contribution of past and active communities to the molecular signal from sedimentary archives. Additionally, a droplet digital PCR (ddPCR) targeting the 16S ribosomal RNA (16S rRNA) gene of the photosynthetic cyanobacterial genera Microcystis was used to explore if RNA signals were from legacy RNA. We posit that the RNA signal is a mixture of legacy RNA, dormant cells, living bacteria and modern-day trace level contaminants that were introduced during sampling and preferentially amplified. The presence of legacy RNA was confirmed by the detection of Microcystis in sediments aged to ~200 years ago. Recent comparisons between 16S rRNA gene metabarcoding and traditional paleo proxies showed that past changes in bacterial communities can be reconstructed from sedimentary archives. The recovery of RNA in the present study has provided new insights into the origin of these signals. However, caution is required during analysis and interpretation of 16S rRNA gene metabarcoding data especially in recent sediments were there are potentially active bacteria.
Collapse
Affiliation(s)
- John K Pearman
- Coastal and Freshwater Group, Cawthron Institute, Nelson, New Zealand
| | - Laura Biessy
- Coastal and Freshwater Group, Cawthron Institute, Nelson, New Zealand
| | | | | | - Andrew Rees
- University of Victoria, Wellington, New Zealand
| | - Susanna A Wood
- Coastal and Freshwater Group, Cawthron Institute, Nelson, New Zealand
| |
Collapse
|
10
|
Pearman JK, Thomson-Laing G, Howarth JD, Vandergoes MJ, Thompson L, Rees A, Wood SA. Investigating variability in microbial community composition in replicate environmental DNA samples down lake sediment cores. PLoS One 2021; 16:e0250783. [PMID: 33939728 PMCID: PMC8092796 DOI: 10.1371/journal.pone.0250783] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2020] [Accepted: 04/14/2021] [Indexed: 01/04/2023] Open
Abstract
Lake sediments are natural archives that accumulate information on biological communities and their surrounding catchments. Paleolimnology has traditionally focussed on identifying fossilized organisms to reconstruct past environments. In the last decade, the application of molecular methodologies has increased in paleolimnological studies, but further research investigating factors such as sample heterogeneity and DNA degradation are required. In the present study we investigated bacterial community heterogeneity (16S rRNA metabarcoding) within depth slices (1-cm width). Sediment cores were collected from three lakes with differing sediment compositions. Samples were collected from a variety of depths which represent a period of time of approximately 1,200 years. Triplicate samples were collected from each depth slice and bacterial 16S rRNA metabarcoding was undertaken on each sample. Accumulation curves demonstrated that except for the deepest (oldest) slices, the combination of three replicate samples were insufficient to characterise the entire bacterial diversity. However, shared Amplicon Sequence Variants (ASVs) accounted for the majority of the reads in each depth slice (max. shared proportional read abundance 96%, 86%, 65% in the three lakes). Replicates within a depth slice generally clustered together in the Non-metric multidimensional scaling analysis. There was high community dissimilarity in older sediment in one of the cores, which was likely due to the laminae in the sediment core not being horizontal. Given that most paleolimnology studies explore broad scale shifts in community structure rather than seeking to identify rare species, this study demonstrates that a single sample is adequate to characterise shifts in dominant bacterial ASVs.
Collapse
Affiliation(s)
- John K. Pearman
- Coastal and Freshwater Group, Cawthron Institute, Nelson, New Zealand
- * E-mail:
| | | | | | | | - Lucy Thompson
- Coastal and Freshwater Group, Cawthron Institute, Nelson, New Zealand
| | - Andrew Rees
- Victoria University of Wellington, Wellington, New Zealand
| | - Susanna A. Wood
- Coastal and Freshwater Group, Cawthron Institute, Nelson, New Zealand
| |
Collapse
|
11
|
Pearman JK, Biessy L, Thomson-Laing G, Waters S, Vandergoes MJ, Howarth JD, Rees A, Moy C, Pochon X, Wood SA. Local factors drive bacterial and microeukaryotic community composition in lake surface sediment collected across an altitudinal gradient. FEMS Microbiol Ecol 2020; 96:5822763. [PMID: 32310266 DOI: 10.1093/femsec/fiaa070] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Accepted: 04/18/2020] [Indexed: 01/04/2023] Open
Abstract
Lake surface sediments are dominated by microorganisms that play significant roles in biogeochemical cycling within lakes. There is limited knowledge on the relative importance of local environmental factors and altitude on bacterial and microeukaryotic community richness and composition in lake sediments. In the present study, surface sediment samples were collected from 40 lakes along an altitude gradient (2-1215 m). Microbial communities were characterized using 16S (bacteria) and 18S (microeukaryotes) rRNA gene metabarcoding. Bacterial and microeukaryotic richness were not correlated with altitude but instead to environmental variables (e.g. area of water in the catchment (bacteria: R = -0.43). For both bacteria and microeukaryotes, dissimilarity in the community structure had a higher correlation to combined environmental variables (without altitude) (bacteria: R = 0.53; microeukaryotes: R = 0.55) than altitude alone (bacteria: R = 0.34; microeukaryotes: R = 0.47). Sediment sulfur and productive grassland were important variables in determining the relative abundance of sulfate reducing bacteria. Nitrospira, was positively related to altitude but negatively to water column total organic carbon and the proportion of productive grassland in the catchment. Little overlap in amplicon sequence variants was shown amongst lakes. This has important considerations for management decisions, suggesting that to protect biodiversity, conservation of numerous lakes and lake types is required.
Collapse
Affiliation(s)
- John K Pearman
- Cawthron Institute, Coastal and Freshwater Group, 95 Halifax Street East, Nelson, 7010, New Zealand
| | - Laura Biessy
- Cawthron Institute, Coastal and Freshwater Group, 95 Halifax Street East, Nelson, 7010, New Zealand
| | - Georgia Thomson-Laing
- Cawthron Institute, Coastal and Freshwater Group, 95 Halifax Street East, Nelson, 7010, New Zealand
| | - Sean Waters
- Cawthron Institute, Coastal and Freshwater Group, 95 Halifax Street East, Nelson, 7010, New Zealand
| | | | - Jamie D Howarth
- Victoria University of Wellington, School of Geography, Environment and Earth Sciences, PO Box 600, Wellington, New Zealand
| | - Andrew Rees
- Victoria University of Wellington, School of Geography, Environment and Earth Sciences, PO Box 600, Wellington, New Zealand
| | - Chris Moy
- University of Otago, Department of Geology, PO Box 56, Dunedin, 9054, New Zealand
| | - Xavier Pochon
- Cawthron Institute, Coastal and Freshwater Group, 95 Halifax Street East, Nelson, 7010, New Zealand.,University of Auckland, Institute of Marine Science, Private Bag 92019, Auckland, 1142, New Zealand
| | - Susanna A Wood
- Cawthron Institute, Coastal and Freshwater Group, 95 Halifax Street East, Nelson, 7010, New Zealand
| |
Collapse
|
12
|
Kaufman D, McKay N, Routson C, Erb M, Davis B, Heiri O, Jaccard S, Tierney J, Dätwyler C, Axford Y, Brussel T, Cartapanis O, Chase B, Dawson A, de Vernal A, Engels S, Jonkers L, Marsicek J, Moffa-Sánchez P, Morrill C, Orsi A, Rehfeld K, Saunders K, Sommer PS, Thomas E, Tonello M, Tóth M, Vachula R, Andreev A, Bertrand S, Biskaborn B, Bringué M, Brooks S, Caniupán M, Chevalier M, Cwynar L, Emile-Geay J, Fegyveresi J, Feurdean A, Finsinger W, Fortin MC, Foster L, Fox M, Gajewski K, Grosjean M, Hausmann S, Heinrichs M, Holmes N, Ilyashuk B, Ilyashuk E, Juggins S, Khider D, Koinig K, Langdon P, Larocque-Tobler I, Li J, Lotter A, Luoto T, Mackay A, Magyari E, Malevich S, Mark B, Massaferro J, Montade V, Nazarova L, Novenko E, Pařil P, Pearson E, Peros M, Pienitz R, Płóciennik M, Porinchu D, Potito A, Rees A, Reinemann S, Roberts S, Rolland N, Salonen S, Self A, Seppä H, Shala S, St-Jacques JM, Stenni B, Syrykh L, Tarrats P, Taylor K, van den Bos V, Velle G, Wahl E, Walker I, Wilmshurst J, Zhang E, Zhilich S. Author Correction: A global database of Holocene paleotemperature records. Sci Data 2020; 7:246. [PMID: 32678108 PMCID: PMC7366677 DOI: 10.1038/s41597-020-00584-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Darrell Kaufman
- Northern Arizona University, School of Earth and Sustainability, Flagstaff, AZ, 86011, USA.
| | - Nicholas McKay
- Northern Arizona University, School of Earth and Sustainability, Flagstaff, AZ, 86011, USA
| | - Cody Routson
- Northern Arizona University, School of Earth and Sustainability, Flagstaff, AZ, 86011, USA
| | - Michael Erb
- Northern Arizona University, School of Earth and Sustainability, Flagstaff, AZ, 86011, USA
| | - Basil Davis
- University of Lausanne, Institute of Earth Surface Dynamics, Lausanne, 1015, Switzerland
| | - Oliver Heiri
- University of Basel, Department of Environmental Sciences, Basel, 4056, Switzerland
| | - Samuel Jaccard
- University of Bern, Institute of Geological Sciences and Oeschger Center for Climate Change Research, Bern, CH-3012, Switzerland
| | - Jessica Tierney
- University of Arizona, Department of Geosciences, Tucson, AZ, 85721, USA
| | - Christoph Dätwyler
- University of Bern, Institute of Geography and Oeschger Centre for Climate Change Research, Bern, 3012, Switzerland
| | - Yarrow Axford
- Northwestern University, Department of Earth and Planetary Sciences, Evanston, IL, 60208, USA
| | - Thomas Brussel
- University of Utah, Department of Geography, Salt Lake City, UT, 84112, USA
| | - Olivier Cartapanis
- University of Bern, Institute of Geological Sciences and Oeschger Center for Climate Change Research, Bern, CH-3012, Switzerland
| | - Brian Chase
- Université de Montpellier, Centre National de la Recherche Scientifique, Institut des Sciences de l'Evolution, Montpellier, 34095, France
| | - Andria Dawson
- Mount Royal University, Department of General Education, Calgary, T3E6K6, Canada
| | - Anne de Vernal
- Université du Québec à Montréal, Geotop-UQAM, Montréal, H3C 3P8, Canada
| | - Stefan Engels
- University of London, Birkbeck, Department of Geography, London, WC1E 7HX, UK
| | - Lukas Jonkers
- University of Bremen, MARUM Center for Marine Environmental Sciences, Bremen, 28359, Germany
| | - Jeremiah Marsicek
- University of Wisconsin-Madison, Department of Geoscience, Madison, WI, 53706, USA
| | | | - Carrie Morrill
- University of Colorado, Cooperative Institute for Research in Environmental Sciences, Boulder, CO, 80309, USA
| | - Anais Orsi
- Laboratoire des Sciences du Climat et de l'Environnement, Université Paris-Saclay, Gif sur Yvette, 91191, France
| | - Kira Rehfeld
- Heidelberg University, Institute of Environmental Physics, Heidelberg, 69221, Germany
| | - Krystyna Saunders
- Australian Nuclear Science and Technology Organisation, Environment, Lucas Heights, 2234, Australia
| | - Philipp S Sommer
- University of Lausanne, Institute of Earth Surface Dynamics, Lausanne, 1015, Switzerland.,Institute for Coastal Research, Helmholtz-Zentrum, Geesthacht, Germany
| | - Elizabeth Thomas
- University at Buffalo, Department of Geology, Buffalo, NY, 14206, USA
| | - Marcela Tonello
- Universidad Nacional de Mar del Plata, Instituto de Investigaciones Marinas y Costeras, Mar del Plata, 7600, Argentina
| | - Mónika Tóth
- Balaton Limnological Institute, Centre for Ecological Research, Tihany, H-8237, Hungary
| | - Richard Vachula
- Brown University, Department of Earth, Environmental and Planetary Sciences, Providence, 2912, USA
| | - Andrei Andreev
- Alfred Wegener Institut Helmholtz Centre for Polar and Marine Research, Polar Terrestrial Environmental Systems, Potsdam, 14473, Germany
| | | | - Boris Biskaborn
- Alfred Wegener Institut Helmholtz Centre for Polar and Marine Research, Polar Terrestrial Environmental Systems, Potsdam, 14473, Germany
| | - Manuel Bringué
- Natural Resources Canada, Geological Survey of Canada, Calgary, AB, T2L 2A7, Canada
| | - Stephen Brooks
- Natural History Museum, Department of Life Sciences, London, SW7 5BD, UK
| | - Magaly Caniupán
- University of Concepcion, Department of Oceanography and COPAS Sur-Austral Program, Concepcion, 4030000, Chile
| | - Manuel Chevalier
- University of Lausanne, Institute of Earth Surface Dynamics, Lausanne, 1015, Switzerland
| | - Les Cwynar
- University of New Brunswick, Department of Biology, Fredericton, NB, E3B 5A3, Canada
| | - Julien Emile-Geay
- University of Southern California, Department of Earth Sciences, Los Angeles, CA, 90089, USA
| | - John Fegyveresi
- Northern Arizona University, School of Earth and Sustainability, Flagstaff, AZ, 86011, USA
| | - Angelica Feurdean
- Goethe University, Department of Physical Geography, Frankfurt am Main, 60438, Germany
| | - Walter Finsinger
- Université de Montpellier, Centre National de la Recherche Scientifique, Institut des Sciences de l'Evolution, Montpellier, 34095, France
| | - Marie-Claude Fortin
- University of Ottawa, Ottawa-Carleton Institute of Biology, Ottawa, K1N6N5, Canada
| | - Louise Foster
- Newcastle University, School of Geography, Politics and Sociology, Newcastle-upon-Tyne, NE17RU, UK.,British Antarctic Survey, Palaeoenvironments and Ice Sheets, Cambridge, CB3 0ET, UK
| | - Mathew Fox
- University of Arizona, School of Anthropology, Tucson, AZ, 85721, USA
| | - Konrad Gajewski
- University of Ottawa, Department of Geography, Environment and Geomatics, Ottawa, K1N6N5, Canada
| | - Martin Grosjean
- University of Bern, Institute of Geography and Oeschger Centre for Climate Change Research, Bern, 3012, Switzerland
| | | | - Markus Heinrichs
- Okanagan College, Department of Geography and Earth and Environmental Science, Kelowna, V1Y 4X8, Canada
| | - Naomi Holmes
- Sheffield Hallam University, Department of the Natural and Built Environment, Sheffield, S1 1WB, UK
| | - Boris Ilyashuk
- University of Innsbruck, Department of Ecology, Innsbruck, 6020, Austria
| | - Elena Ilyashuk
- University of Innsbruck, Department of Ecology, Innsbruck, 6020, Austria
| | - Steve Juggins
- Newcastle University, School of Geography, Politics and Sociology, Newcastle-upon-Tyne, NE17RU, UK
| | - Deborah Khider
- University of Southern California, Information Sciences Institute, Marina Del Rey, CA, 90292, USA
| | - Karin Koinig
- University of Innsbruck, Department of Ecology, Innsbruck, 6020, Austria
| | - Peter Langdon
- University of Southampton, School of Geography and Environmental Science, Southampton, SO17 1BJ, UK
| | | | - Jianyong Li
- Northwest University, China, College of Urban and Environmental Sciences, Xi'an, 710027, China
| | - André Lotter
- University of Bern, Palaeoecology, Bern, CH-3013, Switzerland
| | - Tomi Luoto
- University of Helsinki, Faculty of Biological and Environmental Sciences, Lahti, 15140, Finland
| | - Anson Mackay
- University College London, Department of Geography, London, WC1E 6BT, UK
| | - Eniko Magyari
- Eötvös Loránd University, Department of Environmental and Landscape Geography, Budapest, 1117, Hungary
| | - Steven Malevich
- University of Arizona, Department of Geosciences, Tucson, AZ, 85721, USA
| | - Bryan Mark
- The Ohio State University, Department of Geography and Byrd Polar and Climate Research Center, Columbus, OH, 43210, USA
| | | | - Vincent Montade
- Université de Montpellier, Centre National de la Recherche Scientifique, Institut des Sciences de l'Evolution, Montpellier, 34095, France
| | - Larisa Nazarova
- Potsdam University, Institute of Geosciences, Potsdam, 14476, Germany
| | - Elena Novenko
- Lomonosov Moscow State University, Faculty of Geography, Moscow, 119991, Russia
| | - Petr Pařil
- Masaryk University, Department of Botany and Zoology, Brno, 61137, Czech Republic
| | - Emma Pearson
- Newcastle University, School of Geography, Politics and Sociology, Newcastle-upon-Tyne, NE17RU, UK
| | - Matthew Peros
- Bishop's University, Department of Environment and Geography, Sherbrooke, Quebec, J1M 1Z7, Canada
| | - Reinhard Pienitz
- Université Laval, Department of Geography, Center for Northern Studies, Québec, G1V 0A6, Canada
| | - Mateusz Płóciennik
- University of Lodz, Department of Invertebrate Zoology and Hydrobiology, Lodz, 90-237, Poland
| | - David Porinchu
- University of Georgia, Department of Geography, Athens, GA, 30606, USA
| | - Aaron Potito
- National University of Ireland Galway, School of Geography, Archaeology and Irish Studies, Galway, H91 TK33, Ireland
| | - Andrew Rees
- Victoria University of Wellington, School of Geography, Environment and Earth Sciences, Wellington, 6012, New Zealand
| | - Scott Reinemann
- Sinclair Community College, Geography Department, Dayton, OH, 45402, USA
| | - Stephen Roberts
- British Antarctic Survey, Palaeoenvironments and Ice Sheets, Cambridge, CB3 0ET, UK
| | - Nicolas Rolland
- Fisheries and Ocean Canada, Gulf Fisheries Centre, Moncton, NB, E1C 9B6, Canada
| | - Sakari Salonen
- University of Helsinki, Department of Geosciences and Geography, Helsinki, 00014, Finland
| | - Angela Self
- The Natural History Museum, London, SW7 5BD, UK
| | - Heikki Seppä
- University of Helsinki, Department of Geosciences and Geography, Helsinki, 00014, Finland
| | - Shyhrete Shala
- Stockholm University, Department of Physical Geography, Stockholm, SE-106 91, Sweden
| | | | - Barbara Stenni
- Ca' Foscari University of Venice, Department of Environmental Sciences, Informatics and Statistics, Venezia, 30172, Italy
| | - Liudmila Syrykh
- Herzen State Pedagogical University of Russia, Research Laboratory of the Environmental management, St. Petersburg, 191186, Russia
| | - Pol Tarrats
- Universitat de Barcelona, Departament de Biologia Evolutiva, Ecologia i Ciències Ambientals, Secció Ecologia, Barcelona, 08028, Spain
| | - Karen Taylor
- National University of Ireland Galway, School of Geography, Archaeology and Irish Studies, Galway, H91 TK33, Ireland.,University College Cork, Department of Geography, Cork, Ireland
| | - Valerie van den Bos
- Victoria University of Wellington, School of Geography, Environment and Earth Sciences, Wellington, 6012, New Zealand
| | - Gaute Velle
- NORCE Norwegian Research Centre, LFI, Bergen, 5008, Norway
| | - Eugene Wahl
- US National Oceanic and Atmospheric Administration, National Centers for Environmental Information, Boulder, CO, 80305, USA
| | - Ian Walker
- University of British Columbia, Department of Biology; Department of Earth, Environmental and Geographic Sciences, Kelowna, British Columbia, V1V 1V7, Canada
| | - Janet Wilmshurst
- Landcare Research, Ecosystems and Conservation, Lincoln, 7640, New Zealand
| | - Enlou Zhang
- Chinese Academy of Sciences, Nanjing Institute of Geography and Limnology, Nanjing, 210008, China
| | - Snezhana Zhilich
- Institute of Archaeology and Ethnography, Russian Academy of Sciences, Siberian Branch, Novosibirsk, 630090, Russia
| |
Collapse
|
13
|
Kaufman D, McKay N, Routson C, Erb M, Davis B, Heiri O, Jaccard S, Tierney J, Dätwyler C, Axford Y, Brussel T, Cartapanis O, Chase B, Dawson A, de Vernal A, Engels S, Jonkers L, Marsicek J, Moffa-Sánchez P, Morrill C, Orsi A, Rehfeld K, Saunders K, Sommer PS, Thomas E, Tonello M, Tóth M, Vachula R, Andreev A, Bertrand S, Biskaborn B, Bringué M, Brooks S, Caniupán M, Chevalier M, Cwynar L, Emile-Geay J, Fegyveresi J, Feurdean A, Finsinger W, Fortin MC, Foster L, Fox M, Gajewski K, Grosjean M, Hausmann S, Heinrichs M, Holmes N, Ilyashuk B, Ilyashuk E, Juggins S, Khider D, Koinig K, Langdon P, Larocque-Tobler I, Li J, Lotter A, Luoto T, Mackay A, Magyari E, Malevich S, Mark B, Massaferro J, Montade V, Nazarova L, Novenko E, Pařil P, Pearson E, Peros M, Pienitz R, Płóciennik M, Porinchu D, Potito A, Rees A, Reinemann S, Roberts S, Rolland N, Salonen S, Self A, Seppä H, Shala S, St-Jacques JM, Stenni B, Syrykh L, Tarrats P, Taylor K, van den Bos V, Velle G, Wahl E, Walker I, Wilmshurst J, Zhang E, Zhilich S. A global database of Holocene paleotemperature records. Sci Data 2020; 7:115. [PMID: 32286335 PMCID: PMC7156486 DOI: 10.1038/s41597-020-0445-3] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Accepted: 03/09/2020] [Indexed: 11/28/2022] Open
Abstract
A comprehensive database of paleoclimate records is needed to place recent warming into the longer-term context of natural climate variability. We present a global compilation of quality-controlled, published, temperature-sensitive proxy records extending back 12,000 years through the Holocene. Data were compiled from 679 sites where time series cover at least 4000 years, are resolved at sub-millennial scale (median spacing of 400 years or finer) and have at least one age control point every 3000 years, with cut-off values slackened in data-sparse regions. The data derive from lake sediment (51%), marine sediment (31%), peat (11%), glacier ice (3%), and other natural archives. The database contains 1319 records, including 157 from the Southern Hemisphere. The multi-proxy database comprises paleotemperature time series based on ecological assemblages, as well as biophysical and geochemical indicators that reflect mean annual or seasonal temperatures, as encoded in the database. This database can be used to reconstruct the spatiotemporal evolution of Holocene temperature at global to regional scales, and is publicly available in Linked Paleo Data (LiPD) format.
Collapse
Affiliation(s)
- Darrell Kaufman
- Northern Arizona University, School of Earth and Sustainability, Flagstaff, AZ, 86011, USA.
| | - Nicholas McKay
- Northern Arizona University, School of Earth and Sustainability, Flagstaff, AZ, 86011, USA
| | - Cody Routson
- Northern Arizona University, School of Earth and Sustainability, Flagstaff, AZ, 86011, USA
| | - Michael Erb
- Northern Arizona University, School of Earth and Sustainability, Flagstaff, AZ, 86011, USA
| | - Basil Davis
- University of Lausanne, Institute of Earth Surface Dynamics, Lausanne, 1015, Switzerland
| | - Oliver Heiri
- University of Basel, Department of Environmental Sciences, Basel, 4056, Switzerland
| | - Samuel Jaccard
- University of Bern, Institute of Geological Sciences and Oeschger Center for Climate Change Research, Bern, CH-3012, Switzerland
| | - Jessica Tierney
- University of Arizona, Department of Geosciences, Tucson, AZ, 85721, USA
| | - Christoph Dätwyler
- University of Bern, Institute of Geography and Oeschger Centre for Climate Change Research, Bern, 3012, Switzerland
| | - Yarrow Axford
- Northwestern University, Department of Earth and Planetary Sciences, Evanston, IL, 60208, USA
| | - Thomas Brussel
- University of Utah, Department of Geography, Salt Lake City, UT, 84112, USA
| | - Olivier Cartapanis
- University of Bern, Institute of Geological Sciences and Oeschger Center for Climate Change Research, Bern, CH-3012, Switzerland
| | - Brian Chase
- Université de Montpellier, Centre National de la Recherche Scientifique, Institut des Sciences de l'Evolution, Montpellier, 34095, France
| | - Andria Dawson
- Mount Royal University, Department of General Education, Calgary, T3E6K6, Canada
| | - Anne de Vernal
- Université du Québec à Montréal, Geotop-UQAM, Montréal, H3C 3P8, Canada
| | - Stefan Engels
- University of London, Birkbeck, Department of Geography, London, WC1E 7HX, UK
| | - Lukas Jonkers
- University of Bremen, MARUM Center for Marine Environmental Sciences, Bremen, 28359, Germany
| | - Jeremiah Marsicek
- University of Wisconsin-Madison, Department of Geoscience, Madison, WI, 53706, USA
| | | | - Carrie Morrill
- University of Colorado, Cooperative Institute for Research in Environmental Sciences, Boulder, CO, 80309, USA
| | - Anais Orsi
- Laboratoire des Sciences du Climat et de l'Environnement, Université Paris-Saclay, Gif sur Yvette, 91191, France
| | - Kira Rehfeld
- Heidelberg University, Institute of Environmental Physics, Heidelberg, 69221, Germany
| | - Krystyna Saunders
- Australian Nuclear Science and Technology Organisation, Environment, Lucas Heights, 2234, Australia
| | - Philipp S Sommer
- University of Lausanne, Institute of Earth Surface Dynamics, Lausanne, 1015, Switzerland
- Institute for Coastal Research, Helmholtz-Zentrum, Geesthacht, Germany
| | - Elizabeth Thomas
- University at Buffalo, Department of Geology, Buffalo, NY, 14206, USA
| | - Marcela Tonello
- Universidad Nacional de Mar del Plata, Instituto de Investigaciones Marinas y Costeras, Mar del Plata, 7600, Argentina
| | - Mónika Tóth
- Balaton Limnological Institute, Centre for Ecological Research, Tihany, H-8237, Hungary
| | - Richard Vachula
- Brown University, Department of Earth, Environmental and Planetary Sciences, Providence, 2912, USA
| | - Andrei Andreev
- Alfred Wegener Institut Helmholtz Centre for Polar and Marine Research, Polar Terrestrial Environmental Systems, Potsdam, 14473, Germany
| | | | - Boris Biskaborn
- Alfred Wegener Institut Helmholtz Centre for Polar and Marine Research, Polar Terrestrial Environmental Systems, Potsdam, 14473, Germany
| | - Manuel Bringué
- Natural Resources Canada, Geological Survey of Canada, Calgary, AB, T2L 2A7, Canada
| | - Stephen Brooks
- Natural History Museum, Department of Life Sciences, London, SW7 5BD, UK
| | - Magaly Caniupán
- University of Concepcion, Department of Oceanography and COPAS Sur-Austral Program, Concepcion, 4030000, Chile
| | - Manuel Chevalier
- University of Lausanne, Institute of Earth Surface Dynamics, Lausanne, 1015, Switzerland
| | - Les Cwynar
- University of New Brunswick, Department of Biology, Fredericton, NB, E3B 5A3, Canada
| | - Julien Emile-Geay
- University of Southern California, Department of Earth Sciences, Los Angeles, CA, 90089, USA
| | - John Fegyveresi
- Northern Arizona University, School of Earth and Sustainability, Flagstaff, AZ, 86011, USA
| | - Angelica Feurdean
- Goethe University, Department of Physical Geography, Frankfurt am Main, 60438, Germany
| | - Walter Finsinger
- Université de Montpellier, Centre National de la Recherche Scientifique, Institut des Sciences de l'Evolution, Montpellier, 34095, France
| | - Marie-Claude Fortin
- University of Ottawa, Ottawa-Carleton Institute of Biology, Ottawa, K1N6N5, Canada
| | - Louise Foster
- Newcastle University, School of Geography, Politics and Sociology, Newcastle-upon-Tyne, NE17RU, UK
- British Antarctic Survey, Palaeoenvironments and Ice Sheets, Cambridge, CB3 0ET, UK
| | - Mathew Fox
- University of Arizona, School of Anthropology, Tucson, AZ, 85721, USA
| | - Konrad Gajewski
- University of Ottawa, Department of Geography, Environment and Geomatics, Ottawa, K1N6N5, Canada
| | - Martin Grosjean
- University of Bern, Institute of Geography and Oeschger Centre for Climate Change Research, Bern, 3012, Switzerland
| | | | - Markus Heinrichs
- Okanagan College, Department of Geography and Earth and Environmental Science, Kelowna, V1Y 4X8, Canada
| | - Naomi Holmes
- Sheffield Hallam University, Department of the Natural and Built Environment, Sheffield, S1 1WB, UK
| | - Boris Ilyashuk
- University of Innsbruck, Department of Ecology, Innsbruck, 6020, Austria
| | - Elena Ilyashuk
- University of Innsbruck, Department of Ecology, Innsbruck, 6020, Austria
| | - Steve Juggins
- Newcastle University, School of Geography, Politics and Sociology, Newcastle-upon-Tyne, NE17RU, UK
| | - Deborah Khider
- University of Southern California, Information Sciences Institute, Marina Del Rey, CA, 90292, USA
| | - Karin Koinig
- University of Innsbruck, Department of Ecology, Innsbruck, 6020, Austria
| | - Peter Langdon
- University of Southampton, School of Geography and Environmental Science, Southampton, SO17 1BJ, UK
| | | | - Jianyong Li
- Northwest University, China, College of Urban and Environmental Sciences, Xi'an, 710027, China
| | - André Lotter
- University of Bern, Palaeoecology, Bern, CH-3013, Switzerland
| | - Tomi Luoto
- University of Helsinki, Faculty of Biological and Environmental Sciences, Lahti, 15140, Finland
| | - Anson Mackay
- University College London, Department of Geography, London, WC1E 6BT, UK
| | - Eniko Magyari
- Eötvös Loránd University, Department of Environmental and Landscape Geography, Budapest, 1117, Hungary
| | - Steven Malevich
- University of Arizona, Department of Geosciences, Tucson, AZ, 85721, USA
| | - Bryan Mark
- The Ohio State University, Department of Geography and Byrd Polar and Climate Research Center, Columbus, OH, 43210, USA
| | | | - Vincent Montade
- Université de Montpellier, Centre National de la Recherche Scientifique, Institut des Sciences de l'Evolution, Montpellier, 34095, France
| | - Larisa Nazarova
- Potsdam University, Institute of Geosciences, Potsdam, 14476, Germany
| | - Elena Novenko
- Lomonosov Moscow State University, Faculty of Geography, Moscow, 119991, Russia
| | - Petr Pařil
- Masaryk University, Department of Botany and Zoology, Brno, 61137, Czech Republic
| | - Emma Pearson
- Newcastle University, School of Geography, Politics and Sociology, Newcastle-upon-Tyne, NE17RU, UK
| | - Matthew Peros
- Bishop's University, Department of Environment and Geography, Sherbrooke, Quebec, J1M 1Z7, Canada
| | - Reinhard Pienitz
- Université Laval, Department of Geography, Center for Northern Studies, Québec, G1V 0A6, Canada
| | - Mateusz Płóciennik
- University of Lodz, Department of Invertebrate Zoology and Hydrobiology, Lodz, 90-237, Poland
| | - David Porinchu
- University of Georgia, Department of Geography, Athens, GA, 30606, USA
| | - Aaron Potito
- National University of Ireland Galway, School of Geography, Archaeology and Irish Studies, Galway, H91 TK33, Ireland
| | - Andrew Rees
- Victoria University of Wellington, School of Geography, Environment and Earth Sciences, Wellington, 6012, New Zealand
| | - Scott Reinemann
- Sinclair Community College, Geography Department, Dayton, OH, 45402, USA
| | - Stephen Roberts
- British Antarctic Survey, Palaeoenvironments and Ice Sheets, Cambridge, CB3 0ET, UK
| | - Nicolas Rolland
- Fisheries and Ocean Canada, Gulf Fisheries Centre, Moncton, NB, E1C 9B6, Canada
| | - Sakari Salonen
- University of Helsinki, Department of Geosciences and Geography, Helsinki, 00014, Finland
| | - Angela Self
- The Natural History Museum, London, SW7 5BD, UK
| | - Heikki Seppä
- University of Helsinki, Department of Geosciences and Geography, Helsinki, 00014, Finland
| | - Shyhrete Shala
- Stockholm University, Department of Physical Geography, Stockholm, SE-106 91, Sweden
| | | | - Barbara Stenni
- Ca' Foscari University of Venice, Department of Environmental Sciences, Informatics and Statistics, Venezia, 30172, Italy
| | - Liudmila Syrykh
- Herzen State Pedagogical University of Russia, Research Laboratory of the Environmental management, St. Petersburg, 191186, Russia
| | - Pol Tarrats
- Universitat de Barcelona, Departament de Biologia Evolutiva, Ecologia i Ciències Ambientals, Secció Ecologia, Barcelona, 08028, Spain
| | - Karen Taylor
- National University of Ireland Galway, School of Geography, Archaeology and Irish Studies, Galway, H91 TK33, Ireland
- University College Cork, Department of Geography, Cork, Ireland
| | - Valerie van den Bos
- Victoria University of Wellington, School of Geography, Environment and Earth Sciences, Wellington, 6012, New Zealand
| | - Gaute Velle
- NORCE Norwegian Research Centre, LFI, Bergen, 5008, Norway
| | - Eugene Wahl
- US National Oceanic and Atmospheric Administration, National Centers for Environmental Information, Boulder, CO, 80305, USA
| | - Ian Walker
- University of British Columbia, Department of Biology; Department of Earth, Environmental and Geographic Sciences, Kelowna, British Columbia, V1V 1V7, Canada
| | - Janet Wilmshurst
- Landcare Research, Ecosystems and Conservation, Lincoln, 7640, New Zealand
| | - Enlou Zhang
- Chinese Academy of Sciences, Nanjing Institute of Geography and Limnology, Nanjing, 210008, China
| | - Snezhana Zhilich
- Institute of Archaeology and Ethnography, Russian Academy of Sciences, Siberian Branch, Novosibirsk, 630090, Russia
| |
Collapse
|
14
|
Abstract
Injection moulding is a well-established replication process for the cost-effective manufacture of polymer-based components. The process has different applications in fields such as medical, automotive and aerospace. To expand the use of polymers to meet growing consumer demands for increased functionality, advanced injection moulding processes have been developed that modifies the polymer to create microcellular structures. Through the creation of microcellular materials, additional functionality can be gained through polymer component weight and processing energy reduction. Microcellular injection moulding shows high potential in creating innovation green manufacturing platforms. This review article aims to present the significant developments that have been achieved in different aspects of microcellular injection moulding. Aspects covered include core-back, gas counter pressure, variable thermal tool moulding and other advanced technologies. The resulting characteristics of creating microcellular injection moulding components through both plasticising agents and nucleating agents are presented. In addition, the article highlights potential areas for research exploitation. In particular, acoustic and thermal applications, nano-cellular injection moulding parts and developments of more accurate simulations.
Collapse
Affiliation(s)
| | - Andrew Rees
- College of Engineering, Swansea University, Swansea, UK
| | | | | |
Collapse
|
15
|
Chauhan A, Lalor T, Watson S, Adams D, Farrah TE, Anand A, Kimmitt R, Mills NL, Webb DJ, Dhaun N, Kalla R, Adams A, Vatn S, Bonfliglio F, Nimmo E, Kennedy N, Ventham N, Vatn M, Ricanek P, Halfvarson J, Soderhollm J, Pierik M, Torkvist L, Gomollon F, Gut I, Jahnsen J, Satsangi J, Body R, Almashali M, McDowell G, Taylor P, Lacey A, Rees A, Dayan C, Lazarus J, Nelson S, Okosieme O, Corcoran D, Young R, Ciadella P, McCartney P, Bajrangee A, Hennigan B, Collison D, Carrick D, Shaukat A, Good R, Watkins S, McEntegart M, Watt J, Welsh P, Sattar N, McConnachie A, Oldroyd K, Berry C, Parks T, Auckland K, Mentzer AJ, Kado J, Mirabel MM, Kauwe JK, Robson KJ, Mittal B, Steer AC, Hill AVS, Akbar M, Forrester M, Virlan AT, Gilmour A, Wallace C, Paterson C, Reid D, Siebert S, Porter D, Liversidge J, McInnes I, Goodyear C, Athwal V, Pritchett J, Zaitoun A, Irving W, Guha IN, Hanley NA, Hanley KP, Briggs T, Reynolds J, Rice G, Bondet V, Bruce E, Crow Y, Duffy D, Parker B, Bruce I, Martin K, Pritchett J, Aoibheann Mullan M, Llewellyn J, Athwal V, Zeef L, Farrow S, Streuli C, Henderson N, Friedman S, Hanley N, Hanley KP. Scientific Business Abstracts of the 112th Annual Meeting of the Association of Physicians of Great Britain and Ireland. QJM 2018; 111:920-924. [PMID: 31222346 DOI: 10.1093/qjmed/hcy193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - T Lalor
- From the University of Birmingham
| | - S Watson
- From the University of Birmingham
| | - D Adams
- From the University of Birmingham
| | - T E Farrah
- From the University/British Heart Foundation Centre of Research Excellence, University of Edinburgh
| | - A Anand
- From the University/British Heart Foundation Centre of Research Excellence, University of Edinburgh
| | - R Kimmitt
- From the University/British Heart Foundation Centre of Research Excellence, University of Edinburgh
| | - N L Mills
- From the University/British Heart Foundation Centre of Research Excellence, University of Edinburgh
| | - D J Webb
- From the University/British Heart Foundation Centre of Research Excellence, University of Edinburgh
| | - N Dhaun
- From the University/British Heart Foundation Centre of Research Excellence, University of Edinburgh
| | - R Kalla
- From the University of Edinburgh
| | - A Adams
- From the University of Edinburgh
| | - S Vatn
- Akerhshus University Hospital
| | | | - E Nimmo
- From the University of Edinburgh
| | | | | | | | | | | | | | - M Pierik
- Maastricht University Medical Centre
| | | | | | | | | | | | - R Body
- From the University of Manchester
| | - M Almashali
- Manchester University Hospitals Foundation NHS Trust
| | | | | | | | - A Rees
- From the Cardiff University
| | | | | | | | | | - D Corcoran
- From the British Heart Foundation (BHF), Glasgow Cardiovascular Research Centre, University of Glasgow
| | - R Young
- Robertson Centre for Biostatistics, University of Glasgow
| | - P Ciadella
- West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital
| | - P McCartney
- From the British Heart Foundation (BHF), Glasgow Cardiovascular Research Centre, University of Glasgow
| | - A Bajrangee
- West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital
| | - B Hennigan
- West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital
| | - D Collison
- West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital
| | - D Carrick
- West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital
| | - A Shaukat
- West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital
| | - R Good
- West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital
| | - S Watkins
- West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital
| | - M McEntegart
- West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital
| | - J Watt
- West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital
| | - P Welsh
- From the British Heart Foundation (BHF), Glasgow Cardiovascular Research Centre, University of Glasgow
| | - N Sattar
- From the British Heart Foundation (BHF), Glasgow Cardiovascular Research Centre, University of Glasgow
| | - A McConnachie
- Robertson Centre for Biostatistics, University of Glasgow
| | - K Oldroyd
- West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital
| | - C Berry
- From the British Heart Foundation (BHF), Glasgow Cardiovascular Research Centre, University of Glasgow
| | - T Parks
- From the London School of Hygiene and Tropical Medicine
- University of Oxford
| | | | | | - J Kado
- Fiji Islands Ministry of Health and Medical Services
| | - M M Mirabel
- French National Institute of Health and Medical Research
| | | | | | - B Mittal
- Babasaheb Bhimrao Ambedkar University
| | - A C Steer
- Murdoch Children's Research Institute
| | | | - M Akbar
- From the Institute of Infection, Immunity & Inflammation, University of Glasgow
| | - M Forrester
- Division of Applied Medicine, School of Medicine and Dentistry, University of Aberdeen
| | - A T Virlan
- From the Institute of Infection, Immunity & Inflammation, University of Glasgow
| | - A Gilmour
- From the Institute of Infection, Immunity & Inflammation, University of Glasgow
| | - C Wallace
- Division of Applied Medicine, School of Medicine and Dentistry, University of Aberdeen
| | - C Paterson
- From the Institute of Infection, Immunity & Inflammation, University of Glasgow
| | - D Reid
- Division of Applied Medicine, School of Medicine and Dentistry, University of Aberdeen
| | - S Siebert
- From the Institute of Infection, Immunity & Inflammation, University of Glasgow
| | - D Porter
- From the Institute of Infection, Immunity & Inflammation, University of Glasgow
| | - J Liversidge
- Division of Applied Medicine, School of Medicine and Dentistry, University of Aberdeen
| | - I McInnes
- From the Institute of Infection, Immunity & Inflammation, University of Glasgow
| | - C Goodyear
- From the Institute of Infection, Immunity & Inflammation, University of Glasgow
| | - V Athwal
- From the Manchester University Foundation NHS Trust
- University of Manchester
| | | | | | | | | | - N A Hanley
- From the Manchester University Foundation NHS Trust
- University of Manchester
| | | | - T Briggs
- From the Manchester Centre of Genomic Medicine, University of Manchester
| | - J Reynolds
- Division of Musculoskeletal & Dermatological Sciences, University of Manchester
| | - G Rice
- From the Manchester Centre of Genomic Medicine, University of Manchester
| | - V Bondet
- Immunobiology of Dendritic Cells, Institut Pasteur
| | - E Bruce
- Division of Musculoskeletal & Dermatological Sciences, University of Manchester
| | - Y Crow
- Laboratory of Neurogenetics and Neuroinflammation, INSERM UMR1163, Institut Imagine
| | - D Duffy
- Immunobiology of Dendritic Cells, Institut Pasteur
| | - B Parker
- Division of Musculoskeletal & Dermatological Sciences, University of Manchester
| | - I Bruce
- Division of Musculoskeletal & Dermatological Sciences, University of Manchester
| | - K Martin
- From the University of Manchester
| | | | | | | | - V Athwal
- From the University of Manchester
| | - L Zeef
- From the University of Manchester
| | - S Farrow
- From the University of Manchester
- Respiratory Therapy Area, GlaxoSmithKline
| | | | | | | | - N Hanley
- From the University of Manchester
| | | |
Collapse
|
16
|
Rees A, Fischer-Tenhagen C, Heuwieser W. Udder firmness as a possible indicator for clinical mastitis. J Dairy Sci 2017; 100:2170-2183. [DOI: 10.3168/jds.2016-11940] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2016] [Accepted: 11/22/2016] [Indexed: 12/20/2022]
|
17
|
Hubert V, Peschel A, Langer B, Gröger M, Rees A, Kain R. LAMP-2 is required for incorporating syntaxin-17 into autophagosomes and for their fusion with lysosomes. Biol Open 2016; 5:1516-1529. [PMID: 27628032 PMCID: PMC5087675 DOI: 10.1242/bio.018648] [Citation(s) in RCA: 77] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Autophagy is an evolutionarily conserved process used for removing surplus and damaged proteins and organelles from the cytoplasm. The unwanted material is incorporated into autophagosomes that eventually fuse with lysosomes, leading to the degradation of their cargo. The fusion event is mediated by the interaction between the Qa-SNARE syntaxin-17 (STX17) on autophagosomes and the R-SNARE VAMP8 on lysosomes. Cells deficient in lysosome membrane-associated protein-2 (LAMP-2) have increased numbers of autophagosomes but the underlying mechanism is poorly understood. By transfecting LAMP-2-deficient and LAMP-1/2-double-deficient mouse embryonic fibroblasts (MEFs) with a tandem fluorescent-tagged LC3 we observed a failure of fusion between the autophagosomes and the lysosomes that could be rescued by complementation with LAMP-2A. Although we observed no change in expression and localization of VAMP8, its interacting partner STX17 was absent from autophagosomes of LAMP-2-deficient cells. Thus, LAMP-2 is essential for STX17 expression by the autophagosomes and this absence is sufficient to explain their failure to fuse with lysosomes. The results have clear implications for situations associated with a reduction of LAMP-2 expression. Summary: LAMP-2 is required for autophagosome-lysosome fusion. Its absence does not affect the lysosomal SNARE VAMP8 while its interacting partner STX17 is absent from the autophagosomes providing a molecular explanation for this fusion failure.
Collapse
Affiliation(s)
- Virginie Hubert
- Clinical Institute of Pathology, Medical University of Vienna, Vienna 1090, Austria
| | - Andrea Peschel
- Clinical Institute of Pathology, Medical University of Vienna, Vienna 1090, Austria
| | - Brigitte Langer
- Clinical Institute of Pathology, Medical University of Vienna, Vienna 1090, Austria
| | - Marion Gröger
- Core Facilities, Medical University of Vienna, Vienna 1090, Austria
| | - Andrew Rees
- Clinical Institute of Pathology, Medical University of Vienna, Vienna 1090, Austria
| | - Renate Kain
- Clinical Institute of Pathology, Medical University of Vienna, Vienna 1090, Austria
| |
Collapse
|
18
|
Grigorieva IV, Grigorieva EF, Langer B, Kain R, Rees A. SP043THE ROLE OF GATA3 IN RENIN CELLS IN KIDNEY DEVELOPMENT AND DURING ADAPTATION TO PHYSIOLOGICAL STRESS. Nephrol Dial Transplant 2016. [DOI: 10.1093/ndt/gfw157.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Rees A, Fischer-Tenhagen C, Heuwieser W. Effect of Heat Stress on Concentrations of Faecal Cortisol Metabolites in Dairy Cows. Reprod Domest Anim 2016; 51:392-9. [DOI: 10.1111/rda.12691] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2015] [Accepted: 03/07/2016] [Indexed: 10/21/2022]
Affiliation(s)
- A Rees
- Clinic for Animal Reproduction; Faculty of Veterinary Medicine; Freie Universität Berlin; Berlin Germany
| | - C Fischer-Tenhagen
- Clinic for Animal Reproduction; Faculty of Veterinary Medicine; Freie Universität Berlin; Berlin Germany
| | - W Heuwieser
- Clinic for Animal Reproduction; Faculty of Veterinary Medicine; Freie Universität Berlin; Berlin Germany
| |
Collapse
|
20
|
Abstract
Moh Daha has been instrumental for initiating and coordinating many European consortia in the area of immunopathogenesis of glomerulonephritis including a number with the author. This review provides a personal history of these developments, ending with INTRICATE, an FP7 medium scale project investigating ANCA-associated vasculitis (AAV). The current status of this research and recent insight in the autoimmune reactions and autoantigens in AAV are briefly summarized.
Collapse
Affiliation(s)
- Andrew Rees
- Lately of Clinical Institute of Pathology, Medical University of Vienna, Währinger Gürtel 18-20, A-1109 Vienna, Austria.
| |
Collapse
|
21
|
Grant P, Ayuk J, Bouloux PM, Cohen M, Cranston I, Murray RD, Rees A, Thatcher N, Grossman A. Response to 'How we define hyponatremia?'. Eur J Clin Invest 2015; 45:1218. [PMID: 26343423 DOI: 10.1111/eci.12515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2015] [Accepted: 08/05/2015] [Indexed: 11/30/2022]
Affiliation(s)
- P Grant
- Royal Sussex County Hospital, Brighton, UK
| | - J Ayuk
- Department of Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, UK
| | - P-M Bouloux
- Diabetes and Endocrinology, Royal Free London NHS Foundation Trust, London, UK
| | - M Cohen
- Diabetes and Endocrinology, Royal Free London NHS Foundation Trust, London, UK
| | - I Cranston
- Diabetes and Endocrinology, Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital, Hampshire, UK
| | - R D Murray
- Department of Diabetes and Endocrinology, Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds, UK
| | - A Rees
- Department of Endocrinology and Diabetes, Cardiff University School of Medicine, Cardiff, UK
| | - N Thatcher
- Department of Medical Oncology, Christie Hospital, NHS Trust Manchester, Manchester, UK
| | - A Grossman
- Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford, UK
| |
Collapse
|
22
|
|
23
|
Bunce C, Zekite A, Walton S, Rees A, Patel P. Certifications for sight impairment due to age related macular degeneration in England. Public Health 2015; 129:138-42. [PMID: 25677221 DOI: 10.1016/j.puhe.2014.12.018] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2014] [Revised: 12/22/2014] [Accepted: 12/23/2014] [Indexed: 10/24/2022]
Abstract
OBJECTIVES To examine variability across England in certification rates for age related macular degeneration (AMD) between 1st April 2011 and 31st March 2012. STUDY DESIGN Cross-sectional survey. METHODS An electronic version of the CVI, the ECVI, was used at the Certifications Office, London, to transfer information from paper based certificates into a database. The electronic certifications data set was queried for all certificates completed in England between April 1st 2011 and March 31st 2012 with the main cause of certifiable visual loss being AMD or with the main cause of certifiable visual loss being multiple pathology but a contributory cause being AMD. Data were explored by type of AMD, visual status, age and sex and then directly standardized rates were computed by English region. RESULTS The Certifications Office received 23,616 CVIs for England between April 2011 and March 2012, of which 10,481 (44%) were people certified severely sight-impaired (blind) (SSI) and 12,689 (54%) were certified as sight-impaired (partial sight) (SI). The remainder did not have visual status classified. AMD contributed to 11546 causes of certification on the CVI forms during this period, 53% of forms being for geographic atrophy (GA)/dry AMD which is currently mostly untreatable. The median (interquartile) age at certification for AMD was 86 (81, 90) years and women were more commonly certified than men (66%). Considerable variability was seen across English regions, although there was consistency in that GA was the more common form in all areas. CONCLUSIONS There is considerable regional variability in CVI rates in England, which are not attributable to differences in age or sex. Reasons for such variability need examination yet this should not undermine the value of these data in terms of describing those newly registered with sight impairment due to AMD who are predominantly female and over 85 years of age.
Collapse
|
24
|
Zöllner S, Pablik E, Druml W, Derfler K, Rees A, Biesenbach P. Fibrinogen reduction and bleeding complications in plasma exchange, immunoadsorption and a combination of the two. Blood Purif 2014; 38:160-6. [PMID: 25501972 DOI: 10.1159/000367682] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2014] [Accepted: 08/18/2014] [Indexed: 11/19/2022]
Abstract
BACKGROUND Immunoadsorption (IAS) and therapeutic plasma exchange (TPE) are considered safe although fibrinogen is removed. To date no comparison of fibrinogen reduction and associated risk of bleeding in apheresis exists. METHODS Retrospective analysis of TPE, three IAS adsorbers, and combined TPE/IAS regarding fibrinogen reduction and bleeding incidence in 67 patients (1,032 treatments). RESULTS TPE and TPE/IAS reduced fibrinogen by 64 ± 11% and 58 ± 9%, leading to concentrations <100 mg/dl in 20 and 17% of treatments, respectively. IAS decreased fibrinogen less than TPE (26 ± 6%, p < 0.0001), resulting in fibrinogen concentrations <100 mg/dl in 1% of treatments. The processed volume correlated with reduction in TPE (r = 0.64, p < 0.01), but not in IAS. Bleeding occurred in 1.3% (IAS), 2.3% (TPE) and 3.1% (TPE/IAS) of treatments. CONCLUSION Hypofibrinogenemia occurs in 20% of patients after TPE and TPE/IAS, but rarely after IAS. IAS removes fibrinogen independently of volume processed. Overall, bleeding is rare in apheresis.
Collapse
Affiliation(s)
- Simon Zöllner
- Internal Medicine III/Clinical Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria
| | | | | | | | | | | |
Collapse
|
25
|
Beattie AM, Barber M, Marques E, Greenwood R, Ingram J, Ayres R, Neale J, Rees A, Coleman B, Hickman M. OR09-4 * SCRIPT IN A DAY (SCID) INTERVENTION FOR INDIVIDUALS WHO ARE INJECTING OPIATES: RESULTS FROM A MIXED METHODS FEASIBILITY RANDOMISED CONTROL TRIAL. Alcohol Alcohol 2014. [DOI: 10.1093/alcalc/agu053.43] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Biesenbach P, Kain R, Derfler K, Perkmann T, Soleiman A, Benharkou A, Druml W, Rees A, Säemann MD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with immunoadsorption. PLoS One 2014; 9:e103568. [PMID: 25079220 PMCID: PMC4117516 DOI: 10.1371/journal.pone.0103568] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2014] [Accepted: 07/03/2014] [Indexed: 01/01/2023] Open
Abstract
Background Anti-glomerular basement membrane (GBM) antibody disease may lead to acute crescentic glomerulonephritis with poor renal prognosis. Current therapy favours plasma exchange (PE) for removal of pathogenic antibodies. Immunoadsorption (IAS) is superior to PE regarding efficiency of antibody-removal and safety. Apart from anecdotal data, there is no systemic analysis of the long-term effects of IAS on anti-GBM-disease and antibody kinetics. Objective To examine the long-term effect of high-frequency IAS combined with standard immunosuppression on patient and renal survival in patients with anti-GBM-disease and to quantify antibody removal and kinetics through IAS. Design Retrospective review of patients treated with IAS for anti-GBM-antibody disease confirmed by biopsy and/or anti-GBM-antibodies. Setting University Hospital of Vienna, Austria. Participants 10 patients with anti-GBM-disease treated with IAS. Measurements Patient and renal survival, renal histology, anti-GBM-antibodies. Results Anti-GBM-antibodies were reduced by the first 9 IAS treatments (mean number of 23) to negative levels in all patients. Renal survival was 40% at diagnosis, 70% after the end of IAS, 63% after one year and 50% at the end of observation (mean 84 months, range 9 to 186). Dialysis dependency was successfully reversed in three of six patients. Patient survival was 90% at the end of observation. Conclusion IAS efficiently eliminates anti-GBM-antibodies suggesting non-inferiority to PE with regard to renal and patient survival. Hence IAS should be considered as a valuable treatment option for anti-GBM-disease, especially in patients presenting with a high percentage of crescents and dialysis dependency due to an unusual high proportion of responders.
Collapse
Affiliation(s)
- Peter Biesenbach
- Internal Medicine III/Clinical Division of Nephrology & Dialysis, Medical University of Vienna, Vienna, Austria
- * E-mail:
| | - Renate Kain
- Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
| | - Kurt Derfler
- Internal Medicine III/Clinical Division of Nephrology & Dialysis, Medical University of Vienna, Vienna, Austria
| | - Thomas Perkmann
- Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
| | - Afschin Soleiman
- Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
| | - Alexandra Benharkou
- Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
| | - Wilfred Druml
- Internal Medicine III/Clinical Division of Nephrology & Dialysis, Medical University of Vienna, Vienna, Austria
| | - Andrew Rees
- Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
| | - Marcus D. Säemann
- Internal Medicine III/Clinical Division of Nephrology & Dialysis, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
27
|
Rees A, Fischer-Tenhagen C, Heuwieser W. Evaluation of udder firmness by palpation and a dynamometer. J Dairy Sci 2014; 97:3488-97. [DOI: 10.3168/jds.2013-7424] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2013] [Accepted: 03/05/2014] [Indexed: 11/19/2022]
|
28
|
DeSchoolmeester J, Palming J, Persson T, Pereira MJ, Wallerstedt E, Brown H, Gill D, Renström F, Lundgren M, Svensson MK, Rees A, Eriksson JW. Differences between men and women in the regulation of adipose 11β-HSD1 and in its association with adiposity and insulin resistance. Diabetes Obes Metab 2013; 15:1056-60. [PMID: 23701286 DOI: 10.1111/dom.12137] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/13/2013] [Revised: 03/24/2013] [Accepted: 05/10/2013] [Indexed: 11/28/2022]
Abstract
This study explored sex differences in 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity and gene expression in isolated adipocytes and adipose tissue (AT), obtained via subcutaneous biopsies from non-diabetic subjects [58 M, 64 F; age 48.3 ± 15.3 years, body mass index (BMI) 27.2 ± 3.9 kg/m²]. Relationships with adiposity and insulin resistance (IR) were addressed. Males exhibited higher 11β-HSD1 activity in adipocytes than females, but there was no such difference for AT. In both men and women, adipocyte 11β-HSD1 activity correlated positively with BMI, waist circumference, % body fat, adipocyte size and with serum glucose, triglycerides and low-density lipoprotein:high-density lipoprotein (LDL:HDL) ratio. Positive correlations with insulin, HOMA-IR and haemoglobin A1c (HbA1c) and a negative correlation with HDL-cholesterol were significant only in males. Conversely, 11β-HSD1 activity in AT correlated with several markers of IR and adiposity in females but not in males, but the opposite pattern was found with respect to 11β-HSD1 mRNA expression. This study suggests that there are sex differences in 11β-HSD1 regulation and in its associations with markers of obesity and IR.
Collapse
|
29
|
Czoski-Murray C, Lloyd Jones M, McCabe C, Claxton K, Oluboyede Y, Roberts J, Nicholl JP, Rees A, Reilly CS, Young D, Fleming T. What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature. Health Technol Assess 2013; 16:i-xvi, 1-159. [PMID: 23302507 DOI: 10.3310/hta16500] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND The evidence base which supported the National Institute for Health and Clinical Excellence (NICE) published Clinical Guideline 3 was limited and 50% was graded as amber. However, the use of tests as part of pre-operative work-up remains a low-cost but high-volume activity within the NHS, with substantial resource implications. The objective of this study was to identify, evaluate and synthesise the published evidence on the clinical effectiveness and cost-effectiveness of the routine use of three tests, full blood counts (FBCs), urea and electrolytes tests (U&Es) and pulmonary function tests, in the pre-operative work-up of otherwise healthy patients undergoing minor or intermediate surgery in the NHS. OBJECTIVE The aims of this study were to estimate the clinical effectiveness and cost-effectiveness of routine pre-operative testing of FBC, electrolytes and renal function and pulmonary function in adult patients classified as American Society of Anaesthesiologists (ASA) grades 1 and 2 undergoing elective minor (grade 1) or intermediate (grade 2) surgical procedures; to compare NICE recommendations with current practice; to evaluate the cost-effectiveness of mandating or withdrawing each of these tests in this patient group; and to identify the expected value of information and whether or not it has value to the NHS in commissioning further primary research into the use of these tests in this group of patients. DATA SOURCES The following electronic bibliographic databases were searched: (1) BIOSIS; (2) Cumulative Index to Nursing and Allied Health Literature; (3) Cochrane Database of Systematic Reviews; (4) Cochrane Central Register of Controlled Trials; (5) EMBASE; (6) MEDLINE; (7) MEDLINE In-Process & Other Non-Indexed Citations; (8) NHS Database of Abstracts of Reviews of Effects; (9) NBS Health Technology Assessment Database; and (10) Science Citation Index. To identify grey and unpublished literature, the Cochrane Register of Controlled Trials, National Research Register Archive, National Institute for Health Research Clinical Research Network Portfolio database and the Copernic Meta-search Engine were searched. A large routine data set which recorded the results of tests was obtained from Leeds Teaching Hospitals Trust. REVIEW METHODS A systematic review of the literature was carried out. The searches were undertaken in March to April 2008 and June 2009. Searches were designed to retrieve studies that evaluated the clinical effectiveness and cost-effectiveness of routine pre-operative testing of FBC, electrolytes and renal function and pulmonary function in the above group of patients. A postal survey of current practice in testing patients in this group pre-operatively was undertaken in 2008. An exemplar cost-effectiveness model was constructed to demonstrate what form this would have taken had there been sufficient data. A large routine data set that recorded the results of tests was obtained from Leeds Teaching Hospitals Trust. This was linked to individual patient data with surgical outcomes, and regression models were estimated. RESULTS A comprehensive and systematic search of both the clinical effectiveness and cost-effectiveness literature identified a large number of potentially relevant studies. However, when these studies were subjected to detailed review and quality assessment, it became clear that the literature provides no evidence on the clinical effectiveness and cost-effectiveness of these specific tests in the specific patient groups. The postal survey had a 17% response rate. Results reported that in ASA grade 1, patients aged < 40 years with no comorbidities undergoing minor surgery did not have routine tests for FBC, electrolytes and renal function and pulmonary function. The results from the regression model showed that the frequency of test use was not consistent with the hypothesis of their routine use. FBC tests were performed in only 58% of patients in the data set and U&E testing was carried out in only 57%. LIMITATIONS Systematic searches of the clinical effectiveness and cost-effectiveness literature found that there is no evidence on the clinical effectiveness or cost-effectiveness of these tests in this specific clinical context for the NHS. A survey of NHS hospitals found that respondent trusts were implementing current NICE guidance in relation to pre-operative testing generally, and a de novo analysis of routine data on test utilisation and post-operative outcome found that the tests were not be used in routine practice; rather, use was related to an expectation of a more complex clinical case. The paucity of published evidence is a limitation of this study. The studies included relied on non-UK health-care systems data, which may not be transferable. The inclusion of non-randomised studies is associated with an increased risk of bias and confounding. Scoping work to establish the likely mechanism of action by which tests would impact upon outcomes and resource utilisation established that the cause of an abnormal test result is likely to be a pivotal determinant of the cost-effectiveness of a pre-operative test and therefore evaluations would need to consider tests in the context of the underlying risk of specific clinical problems (i.e. risk guided rather than routine use). CONCLUSIONS The time of universal utilisation of pre-operative tests for all surgical patients is likely to have passed. The evidence we have identified, though weak, indicates that tests are increasingly utilised in patients in whom there is a reason to consider an underlying raised risk of a clinical abnormality that should be taken into account in their clinical management. It is likely that this strategy has led to substantial resource savings for the NHS, although there is not a published evidence base to establish that this is the case. The total expenditure on pre-operative tests across the NHS remains significant. Evidence on current practice indicates that clinical practice has changed to such a degree that the original research question is no longer relevant to UK practice. Future research on the value of these tests in pre-operative work-up should be couched in terms of the clinical effectiveness and cost-effectiveness in the identification of specific clinical abnormalities in patients with a known underlying risk. We suggest that undertaking a multicentre study making use of linked, routinely collected data sets would identify the extent and nature of pre-operative testing in this group of patients. FUNDING The National Institute for Health Research Health Technology Assessment programme.
Collapse
Affiliation(s)
- C Czoski-Murray
- Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Messina J, Freeman C, Rees A, Goyder E, Hoy A, Ellis S, Ainsworth N. A Systematic Review of Contextual Factors Relating to Smokeless Tobacco Use Among South Asian Users in England. Nicotine Tob Res 2012; 15:875-82. [DOI: 10.1093/ntr/nts193] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
31
|
Whatley S, Haralambos K, Yarram L, Williams M, Greenslade M, Palacios L, Datta D, Rees A, Townsend D, McDowell I. (27) DNA sequence variant c.932A>C, p.Lys311Thr in LDLR gene in familial hypercholesterolaemia (FH): Observations from family studies. Atherosclerosis 2012. [DOI: 10.1016/j.atherosclerosis.2012.06.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
32
|
Ara R, Blake L, Gray L, Hernández M, Crowther M, Dunkley A, Warren F, Jackson R, Rees A, Stevenson M, Abrams K, Cooper N, Davies M, Khunti K, Sutton A. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. Health Technol Assess 2012; 16:iii-xiv, 1-195. [PMID: 22340890 DOI: 10.3310/hta16050] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Obesity [defined as a body mass index (BMI) ≥ 30 kg/m(2)] represents a considerable public health problem and is associated with a significant range of comorbidities and an increased mortality risk. The primary aim of the management of obesity is to achieve weight reduction in the interests of health. For obese patients who cannot achieve or maintain a healthy weight by non-pharmacological means, drug therapy is recommended in combination with non-pharmacological interventions such as dietary modifications and exercise. OBJECTIVE To evaluate the clinical effectiveness and cost-effectiveness of three pharmacological interventions in obese patients. DATA SOURCES Clinical effectiveness data used in the meta-analysis were sourced from articles identified in a systematic review of the literature. Data used to inform transitions to obesity-related comorbidities were derived from the General Practice Research Database (GPRD). The results of the meta-analysis and GPRD analyses informed the economic model supplemented by data from the Health Survey for England and other UK-specific data sourced from the literature. REVIEW METHODS A systematic literature review was conducted of the clinical effectiveness and cost-effectiveness of orlistat, sibutramine and rimonabant within their licensed indications for the treatment of obese patients. Electronic bibliographic databases including MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, The Cochrane Library databases and Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched in January 2009, and the reference lists of relevant articles were checked. Studies were included if they compared orlistat, sibutramine or rimonabant with lifestyle and/or exercise advice (standard care), placebo or metformin. RESULTS Overall, 94 studies involving 24,808 individuals were included in the clinical meta-analysis. Eighty-three trials included data on weight change, 41 included data on BMI change and 45 and 36 studies reported on 5% and 10% body weight loss, respectively. Overall, the results show that the active drug interventions are all effective at reducing weight and BMI compared with placebo. In the case of sibutramine, the higher dose (15 mg) resulted in a greater reduction than the lower dose (10 mg). Generally, the data quality of the trials included was low with poor reporting of standard errors and standard deviations. Results from the BMI risk models derived from the GPRD showed consistent increases in risk with increasing BMI. Adjustments for key confounders, such as age, sex and smoking status, were found to be statistically significant at the 5% level, in all risk models. Applying linear models to estimate BMI trajectories, for the diabetic cohort, an average increase in BMI of 0.040 per year for both men and women was observed. The non-diabetic cohort model showed an increase in BMI of 0.175 per year for women and 0.145 per year for men. The results of the cost-effectiveness analyses suggest that sibutramine 15 mg dominates the other three active interventions and the net benefit analyses show that sibutramine 15 mg is the most cost-effective alternative for thresholds > £2000 per quality-adjusted life-year (QALY). However, both sibutramine and rimonabant have been withdrawn because of safety concerns relating to potential treatment-induced fatal adverse events. If the proportion of patients who experienced a fatal adverse event was > 1.8% (1.5%, 1.0%) for sibutramine 15 mg (sibutramine 10 mg, rimonabant) the treatment would not be considered cost-effective when using a threshold of £20,000 per QALY. LIMITATIONS The clinical review did not include all possible lifestyle comparators, with the inclusion limited to only those trials included one of the active drug interventions. We also excluded all studies not reported in English. Although the clinical review included data from 94 studies, the quality of data was generally low, particularly in terms of the reporting of standard deviation. There was also inconsistency between the results of the mixed-treatment comparison (MTC) and the pair-wise analyses. CONCLUSION The MTC of anti-obesity treatments shows that all the active treatments are effective at reducing weight and BMI. The economic results show that, compared with placebo, the treatments are all cost-effective when using a threshold of £20,000 per QALY, and, within the limitations of the data available, sibutramine 15 mg dominates the other three interventions. This work has highlighted many areas of methodological research that could be explored, including assessing inconsistencies within a network to determine differences between the results of pair-wise and MTC analyses; the use of meta-regression methods to look for effect modifiers; exploring the effect of local publication bias; and the use of joint models to analyse the repeated measures of BMI and the time-to-event processes simultaneously. FUNDING The National Institute for Health Research Health Technology Assessment programme.
Collapse
Affiliation(s)
- R Ara
- School of Health and Related Research, University of Sheffield, Sheffield, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Franks K, Rees A, Fleming C, Trigwell K, Snee M. 90 Retrospective audit of radically treated non-small cell lung cancer (NSCLC) patients at the St James's Institute of Oncology (SJIO), Leeds Teaching Hospital NHS Trust (LTHT). Lung Cancer 2012. [DOI: 10.1016/s0169-5002(12)70091-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
34
|
Pandor A, Goodacre S, Harnan S, Holmes M, Pickering A, Fitzgerald P, Rees A, Stevenson M. Diagnostic management strategies for adults and children with minor head injury: a systematic review and an economic evaluation. Health Technol Assess 2011; 15:1-202. [PMID: 21806873 DOI: 10.3310/hta15270] [Citation(s) in RCA: 85] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Patients with minor head injury [Glasgow Coma Scale (GCS) score 13-15] have a small but important risk of intracranial injury (ICI) that requires early identification and neurosurgical treatment. Diagnostic assessment can use either a clinical decision rule or unstructured assessment of individual clinical features to identify those who are at risk of ICI and in need of computerised tomography (CT) scanning and/or hospital admission. Selective use of CT investigations helps minimise unnecessary radiation exposure and resource use, but can lead to missed opportunities to provide early treatment for ICI. OBJECTIVES To determine the diagnostic accuracy of decision rules, individual clinical characteristics, skull radiography and biomarkers, and the clinical effectiveness and cost-effectiveness of diagnostic management strategies for minor head injury (MHI). DATA SOURCES Several electronic databases [including MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE and The Cochrane Library] were searched from inception to April 2009 (updated searches to March 2010 were conducted on the MEDLINE databases only). Searches were supplemented by hand-searching relevant articles (including citation searching) and contacting experts in the field. For each of the systematic reviews the following studies were included (1) cohort studies of patients with MHI in which a clinical decision rule or individual clinical characteristics (including biomarkers and skull radiography) were compared with a reference standard test for ICI or need for neurosurgical intervention and (2) controlled trials comparing alternative management strategies for MHI. REVIEW METHODS Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool (for the assessment of diagnostic accuracy) or criteria recommended by the Effective Practice and Organisation of Care Review Group (for the assessment of management practices). Where sufficient data existed, a meta-analysis was undertaken to generate pooled estimates of diagnostic parameters. A decision-analysis model was developed using Simul8 2008 Professional software (Simul8 Corporation, Boston, MA, USA) to estimate the costs and quality-adjusted life-years (QALYs) accrued by management strategies for MHI. The model took a lifetime horizon and NHS perspective. Estimates of the benefits of early treatment, harm of radiation exposure and long-term costs were obtained through literature reviews. Initial analysis was deterministic, but probabilistic sensitivity analysis was also performed. Secondary analyses were undertaken to explore the trade-off between sensitivity and specificity in diagnostic strategies and to determine the cost-effectiveness of scenarios involving hospital admission. RESULTS The literature searches identified 8003 citations. Of these, 93 full-text papers were included for the assessment of diagnostic accuracy and one for the assessment of management practices. The quality of studies and reporting was generally poor. The Canadian CT Head Rule (CCHR) was the most widely validated adult rule, with sensitivity of 99-100% and 80-100% for neurosurgical and any ICI, respectively (high- or medium-risk criteria), and specificity of 39-51%. Rules for children had high sensitivity and acceptable specificity in derivation cohorts, but limited validation. Depressed, basal or radiological skull fracture and post-traumatic seizure (PTS) [positive likelihood ratio (PLR) > 10]; focal neurological deficit, persistent vomiting, decrease in GCS and previous neurosurgery (PLR 5-10); and fall from a height, coagulopathy, chronic alcohol use, age > 60 years, pedestrian motor vehicle accident (MVA), any seizure, undefined vomiting, amnesia, GCS < 14 and GCS < 15 (PLR 2-5) increased the likelihood of ICI in adults. Depressed or basal skull fracture and focal neurological deficit (PLR > 10), coagulopathy, PTS and previous neurosurgery (PLR 5-10), visual symptoms, bicycle and pedestrian MVA, any seizure, loss of consciousness, vomiting, severe or persistent headache, amnesia, GCS < 14, GCS < 15, intoxication and radiological skull fracture (PLR 2-5) increased the likelihood of ICI in children. S100 calcium-binding protein B had pooled sensitivity of 96.8% [95% highest-density region (HDR) 93.8% to 98.6%] and specificity of 42.5% (95% HDR 31.0% to 54.2%). The only controlled trial showed that early CT and discharge is cheaper and at least as effective as hospital admission. Economic analysis showed that selective CT use dominated 'CT all' and 'discharge all' strategies. The optimal strategies were the CCHR (adults) and the CHALICE (Children's Head injury Algorithm for the prediction of Important Clinical Events) or NEXUS II (National Emergency X-Radiography Utilization Study II) rule (children). The sensitivity and specificity of the CCHR (99% and 47%, respectively) represented an appropriate trade-off of these parameters. Hospital admission dominated discharge home for patients with non-neurosurgical injury, but cost £39 M per QALY for clinically normal patients with a normal CT. CONCLUSIONS The CCHR is widely validated and cost-effective for adults. Decision rules for children appear cost-effective, but need further validation. Hospital admission is cost-effective for patients with abnormal, but not normal, CT. The main research priorities are to (1) validate decision rules for children; (2) determine the prognosis and treatment benefit for non-neurosurgical injuries; (3) evaluate the use of S100B alongside a validated decision rule; (4) evaluate the diagnosis and outcomes of anticoagulated patients with MHI; and (5) evaluate the implementation of guidelines, clinical decision rules and diagnostic strategies. Formal expected value of sample information analysis would be recommended to appraise the cost-effectiveness of future studies. FUNDING The National Institute for Health Research Health Technology Assessment programme.
Collapse
Affiliation(s)
- A Pandor
- School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Carroll C, Papaioannou D, Rees A, Kaltenthaler E. The clinical effectiveness and safety of prophylactic retinal interventions to reduce the risk of retinal detachment and subsequent vision loss in adults and children with Stickler syndrome: a systematic review. Health Technol Assess 2011; 15:iii-xiv, 1-62. [PMID: 21466760 DOI: 10.3310/hta15160] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Stickler syndrome, also known as hereditary progressive arthro-ophthalmopathy, is an inherited progressive disorder of the collagen connective tissues. Manifestations include short-sightedness, cataracts, retinal problems leading to retinal detachment and possible blindness. This is principally the case among individuals with type 1 Stickler Syndrome. It is the most commonly identified inherited cause of retinal detachment in childhood. However, there is no consensus regarding best practice and no current guidelines on prophylactic interventions for this population. OBJECTIVES The aim of this systematic review was to assess the evidence for the clinical effectiveness and safety of primary prophylactic interventions for the prevention of retinal detachment in previously untreated eyes without retinal detachment in patients with Stickler syndrome. The primary outcome of interest was retinal detachment post prophylaxis. DATA SOURCES A systematic search was made of 11 databases of published and unpublished literature, which included MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, the Cumulative Index to Nursing and Allied Health Literature and The Cochrane Library. There was no restriction by language or date. The references of all included studies were checked for further relevant citations and authors of studies with potentially relevant data were also contacted. REVIEW METHODS Two reviewers double-screened all titles and abstracts of the citations retrieved by the search to identify studies that satisfied the inclusion criteria. Both reviewers also independently extracted and quality assessed all included studies. A narrative synthesis was performed. RESULTS The literature search identified 1444 unique citations, of which four studies satisfied the inclusion criteria. The two principal studies were both retrospective cohort studies with control groups in populations with type 1 Stickler syndrome. One study evaluated 360° cryotherapy (n = 204) and the other focal or circumferential laser treatment (n = 22). Both studies reported a statistically significant difference in the rate of retinal detachment per eye between the groups receiving prophylaxis and the controls. However, both studies were subject to a high risk of bias. The results of the two supporting studies of Wagner-Stickler patients were either relatively inconsistent or unreliable. No study reported any major or long-term complications associated with the interventions. Despite the weaknesses of the evidence, the rate of retinal detachment in the intervention groups, especially the cryotherapy group, was lower than the rate either experienced in the study control groups or reported in other studies of untreated Stickler syndrome populations not exposed to prophylaxis. CONCLUSIONS Only 360° cryotherapy and focal and circumferential laser treatment have been evaluated for the type 1 Stickler syndrome population, and then only by a single retrospective, controlled, cohort study in each case. Both of these studies report a significant difference between intervention and control groups (principally no treatment) and no major or long-term side effects or complications. However, there is a high risk of bias within these two studies, so the relative effectiveness of either intervention is uncertain. FUTURE WORK A service priority is to determine reliably the prevalence of Stickler syndrome, i.e. how many individuals have type 1 or type 2 Stickler syndrome, and their risk of retinal detachment and subsequent blindness. A non-randomised, prospective cohort comparison study, in which eligible participants are treated, followed-up and analysed in one of three study arms, for no treatment, laser therapy or cryotherapy, would potentially offer further certainty in terms of the relative efficacy of both prophylaxis versus no prophylaxis and cryotherapy versus laser therapy than is possible with the currently available data. Alternatively, continued follow-up and analysis of existing study data, and data collection from relevant sample populations, are required to assess the long-term risks of blindness, retinal detachment and prophylaxis. FUNDING This study was funded by the National Institute for Health Research Health Technology Assessment programme.
Collapse
Affiliation(s)
- C Carroll
- The University of Sheffield, School of Health and Related Research (ScHARR), Sheffield, UK
| | | | | | | |
Collapse
|
36
|
Ara R, Pandor A, Stevens J, Rafia R, Ward SE, Rees A, Durrington PN, Reynolds TM, Wierzbicki AS, Stevenson M. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy? Eur J Prev Cardiol 2011; 19:474-83. [PMID: 21460076 DOI: 10.1177/1741826711406616] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND While evidence shows high-dose statins reduce cardiovascular events compared with moderate doses in individuals with acute coronary syndrome (ACS), many primary care trusts (PCT) advocate the use of generic simvastatin 40 mg/day for these patients. METHODS AND RESULTS Data from 28 RCTs were synthesized using a mixed treatment comparison model. A Markov model was used to evaluate the cost-effectiveness of treatments taking into account adherence and the likely reduction in cost for atorvastatin when the patent expires. There is a clear dose-response: rosuvastatin 40 mg/day produces the greatest reduction in low-density lipoprotein cholesterol (56%) followed by atorvastatin 80 mg/day (52%), and simvastatin 40 mg/day (37%). Using a threshold of £20,000 per QALY, if adherence levels in general practice are similar to those observed in RCTs, all three higher dose statins would be considered cost-effective compared to simvastatin 40 mg/day. Using the net benefits of the treatments, rosuvastatin 40 mg/day is estimated to be the most cost-effective alternative. If the cost of atorvastatin reduces in line with that observed for simvastatin, atorvastatin 80 mg/day is estimated to be the most cost-effective alternative. CONCLUSION Our analyses show that current PCT policies intended to minimize primary care drug acquisition costs result in suboptimal care.
Collapse
Affiliation(s)
- R Ara
- School of Health & Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
de Lloyd L, Bovington R, Kaye A, Collis R, Rayment R, Sanders J, Rees A, Collins P. Standard haemostatic tests following major obstetric haemorrhage. Int J Obstet Anesth 2011; 20:135-41. [DOI: 10.1016/j.ijoa.2010.12.002] [Citation(s) in RCA: 137] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2010] [Revised: 10/15/2010] [Accepted: 12/14/2010] [Indexed: 11/25/2022]
|
38
|
Whyte S, Pandor A, Stevenson M, Rees A. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer. Health Technol Assess 2011; 14:47-53. [PMID: 21047491 DOI: 10.3310/hta14suppl2/07] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer based on the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. Evidence was available in the form of one phase III, multicentre, multinational, randomised, open-label study (NO16966 trial). This two-arm study was originally designed to demonstrate the non-inferiority of oral capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil plus folinic acid plus oxaliplatin (FOLFOX)-4 in adult patients with histologically confirmed metastatic colorectal cancer who had not previously been treated. Following randomisation of 634 patients, the open-label study was amended to include a 2 × 2 factorial randomised (partially blinded for bevacizumab) phase III trial with the coprimary objective of demonstrating superiority of bevacizumab in combination with chemotherapy compared with chemotherapy alone. Measured outcomes included overall survival, progression-free survival, response rate, adverse effects of treatment and health-related quality of life. The manufacturer's primary pooled analysis of superiority (using the intention-to-treat population) showed that after a median follow-up of 28 months, the addition of bevacizumab to chemotherapy significantly improved progression-free survival and overall survival compared with chemotherapy alone in adult patients with histologically confirmed metastatic colorectal cancer who were not previously treated [median progression-free survival 9.4 vs 7.7 months (absolute difference 1.7 months); hazard ratio (HR) 0.79, 97.5% confidence interval (CI) 0.72 to 0.87; p = 0.0001; median overall survival 21.2 vs 18.9 months (absolute difference 2.3 months); HR 0.83, 97.5% CI 0.74 to 0.93; p = 0.0019]. The NO16966 trial was of reasonable methodological quality and demonstrated a significant improvement in both progression-free survival and overall survival when bevacizumab was added to XELOX or FOLFOX. However, the size of the actual treatment effect of bevacizumab is uncertain. The ERG believed that the modelling structure employed was appropriate, but highlighted several key issues and areas of uncertainty. At the time of writing, NICE was yet to issue the guidance for this appraisal.
Collapse
Affiliation(s)
- S Whyte
- ScHARR Technology Assessment Group, The University of Sheffield, Sheffield, UK.
| | | | | | | |
Collapse
|
39
|
Hummel S, Simpson EL, Hemingway P, Stevenson MD, Rees A. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess 2011; 14:1-108, iii-iv. [PMID: 21029717 DOI: 10.3310/hta14470] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Prostate cancer (PC) is the most common cancer in men in the UK. Radiotherapy (RT) is a recognised treatment for PC and high-dose conformal radiotherapy (CRT) is the recommended standard of care for localised or locally advanced tumours. Intensity-modulated radiotherapy (IMRT) allows better dose distributions in RT. OBJECTIVE This report evaluates the clinical effectiveness and cost-effectiveness of IMRT for the radical treatment of PC. DATA SOURCES The following databases were searched: MEDLINE (1950-present), EMBASE (1980-present), Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1982-present), BIOSIS (1985-present), the Cochrane Database of Systematic Reviews (1991-present), the Cochrane Controlled Trials Register (1991-present), the Science Citation Index (1900-present) and the NHS Centre for Reviews and Dissemination databases (Database of Abstracts of Reviews of Effects, NHS Economic Evaluation Database, Health Technology Assessment) (1991-present). MEDLINE In-Process & Other Non-Indexed Citations was searched to identify any studies not yet indexed on MEDLINE. Current research was identified through searching the UK Clinical Research Network, National Research Register archive, the Current Controlled Trials register and the Medical Research Council Clinical Trials Register. In addition, abstracts of the American Society of Clinical Oncology, the American Society for Therapeutic Radiology and Oncology, and European Society for Therapeutic Radiology and Oncology conferences were browsed. REVIEW METHODS A systematic literature review of the clinical effectiveness and cost-effectiveness of IMRT in PC was conducted. Comparators were three-dimensional conformal radiotherapy (3DCRT) or radical prostatectomy. Outcomes sought were overall survival, biochemical [prostate-specific antigen (PSA)] relapse-free survival, toxicity and health-related quality of life (HRQoL). Fifteen electronic bibliographic databases were searched in January 2009 and updated in May 2009, and the reference lists of relevant articles were checked. Studies only published in languages other than English were excluded. An economic model was developed to examine the cost-effectiveness of IMRT in comparison to 3DCRT. Four scenarios were modelled based on the studies which reported both PSA survival and late gastrointestinal (GI) toxicity. In two scenarios equal PSA survival was assumed for IMRT and 3DCRT, the other two having greater PSA survival for the IMRT cohort. As there was very limited data on clinical outcomes, the model estimates progression to clinical failure and PC death from the surrogate outcome of PSA failure. RESULTS No randomised controlled trials (RCTs) of IMRT versus 3DCRT in PC were available, but 13 non-randomised studies comparing IMRT with 3DCRT were found, of which five were available only as abstracts. One abstract reported overall survival. Biochemical relapse-free survival was not affected by treatment group, except where there was a dose difference between groups, in which case higher dose IMRT was favoured over lower dose 3DCRT. Most studies reported an advantage for IMRT in GI toxicity, attributed to increased conformality of treatment compared with 3DCRT, particularly with regard to volume of rectum treated. There was some indication that genitourinary toxicity was worse for patients treated with dose escalated IMRT, although most studies did not find a significant treatment effect. HRQoL improved for both treatment groups following radiotherapy, with any group difference resolved by 6 months after treatment. No comparative studies of IMRT versus prostatectomy were identified. No comparative studies of IMRT in PC patients with bone metastasis were identified. LIMITATIONS The strength of the conclusions of this review are limited by the lack of RCTs, and any comparative studies for some patient groups. CONCLUSIONS The comparative data of IMRT versus 3DCRT seem to support the theory that higher doses, up to 81 Gy, can improve biochemical survival for patients with localised PC, concurring with data on CRT. The data also suggest that toxicity can be reduced by increasing conformality of treatment, particularly with regard to GI toxicity, which can be more easily achieved with IMRT than 3DCRT. Whether differences in GI toxicity between IMRT and 3DCRT are sufficient for IMRT to be cost-effective is uncertain, depending on the difference in incidence of GI toxicity, its duration and the cost difference between IMRT and 3DCRT.
Collapse
Affiliation(s)
- S Hummel
- School of Health and Related Research, The University of Sheffield, Sheffield, UK
| | | | | | | | | |
Collapse
|
40
|
Whyte S, Pandor A, Stevenson M, Rees A. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer. Health Technol Assess 2010. [DOI: 10.3310/hta14suppl2-07] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer based on the manufacturer’s submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. Evidence was available in the form of one phase III, multicentre, multinational, randomised, open-label study (NO16966 trial). This two-arm study was originally designed to demonstrate the non-inferiority of oral capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil plus folinic acid plus oxaliplatin (FOLFOX)-4 in adult patients with histologically confirmed metastatic colorectal cancer who had not previously been treated. Following randomisation of 634 patients, the open-label study was amended to include a 2 × 2 factorial randomised (partially blinded for bevacizumab) phase III trial with the coprimary objective of demonstrating superiority of bevacizumab in combination with chemotherapy compared with chemotherapy alone. Measured outcomes included overall survival, progression-free survival, response rate, adverse effects of treatment and health-related quality of life. The manufacturer’s primary pooled analysis of superiority (using the intention-to-treat population) showed that after a median follow-up of 28 months, the addition of bevacizumab to chemotherapy significantly improved progression-free survival and overall survival compared with chemotherapy alone in adult patients with histologically confirmed metastatic colorectal cancer who were not previously treated [median progression-free survival 9.4 vs 7.7 months (absolute difference 1.7 months); hazard ratio (HR) 0.79, 97.5% confidence interval (CI) 0.72 to 0.87; p = 0.0001; median overall survival 21.2 vs 18.9 months (absolute difference 2.3 months); HR 0.83, 97.5% CI 0.74 to 0.93; p = 0.0019]. The NO16966 trial was of reasonable methodological quality and demonstrated a significant improvement in both progression-free survival and overall survival when bevacizumab was added to XELOX or FOLFOX. However, the size of the actual treatment effect of bevacizumab is uncertain. The ERG believed that the modelling structure employed was appropriate, but highlighted several key issues and areas of uncertainty. At the time of writing, NICE was yet to issue the guidance for this appraisal.
Collapse
Affiliation(s)
- S Whyte
- ScHARR Technology Assessment Group, The University of Sheffield, Sheffield, UK
| | - A Pandor
- ScHARR Technology Assessment Group, The University of Sheffield, Sheffield, UK
| | - M Stevenson
- ScHARR Technology Assessment Group, The University of Sheffield, Sheffield, UK
| | - A Rees
- ScHARR Technology Assessment Group, The University of Sheffield, Sheffield, UK
| |
Collapse
|
41
|
Sjöstrand M, Jansson PA, Palming J, de Schoolmeester J, Gill D, Rees A, Sjögren L, Persson T, Eriksson JW. Repeated measurements of 11β-HSD-1 activity in subcutaneous adipose tissue from lean, abdominally obese, and type 2 diabetes subjects--no change following a mixed meal. Horm Metab Res 2010; 42:798-802. [PMID: 20514603 DOI: 10.1055/s-0030-1254134] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
The aim of this study was to measure 11β-HSD-1 activity in subcutaneous adipose tissue by an ex vivo method in three subgroups; lean, obese, and type 2 diabetes subjects, both in the fasting state and after a mixed meal and to determine the variability and reproducibility of this method. Eighteen subjects were investigated; 6 lean, 6 abdominally obese, and 6 type 2 diabetes subjects (BMI 22 ± 1, 30 ± 3 and 31 ± 3 kg/m², respectively). Needle biopsies were taken repeatedly and an index of 11β-HSD-1 activity was measured as percent conversion of (3)H-cortisone to (3)H-cortisol/100 mg tissue. For two separate biopsies taken in the fasting state on the same day, the within subjects CV was 16% and the between CV was 36% for 11β-HSD-1 activity for all subjects. For two biopsies taken in the fasting state at two different days, the total within subjects CV was 38% and the between subjects CV was 46%. Lean subjects had lower 11β-HSD-1 activity (4.8 ± 1.5% conversion of ³H-cortisone to ³H-cortisol/100 mg tissue) than both obese (14.4 ± 1.6% conversion, p<0.01) and type 2 diabetes subjects (11.7 ± 1.9% conversion, p<0.05) in the fasting state. There was no effect of a meal on 11β-HSD-1 activity in any of the three groups. The conclusions from this study are: 1) the variation coefficient for the ex vivo adipose tissue 11β-HSD-1 activity method was ∼25% for repeat measures within subjects; 2) food intake had no major impact on enzyme activity; and 3) 11β-HSD-1 activity in subcutaneous adipose tissue was significantly increased in obese subjects with or without T2DM compared to lean subjects without diabetes.
Collapse
|
42
|
Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technol Assess 2010; 13 Suppl 3:43-8. [PMID: 19846028 DOI: 10.3310/hta13suppl3/07] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of rivaroxaban for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The submission's evidence came from four randomised controlled trials (RCTs) comparing rivaroxaban with enoxaparin [RECORD (Regulation of Coagulation in Orthopedic surgery to pRevent Deep venous thrombosis and pulmonary embolism) 1-4] and three comparing dabigatran with enoxaparin [RE-NOVATE (the prevention of venous thromboembolism after total hip replacement trial), RE-MODEL (the prevention of venous thromboembolism after total knee replacement trial) and RE-MOBILIZE (the prevention of venous thromboembolism after total knee arthroplasty trial)]. The evidence from the four RECORD trials indicates that rivaroxaban had superior efficacy over enoxaparin after total hip replacement (THR) and total knee replacement (TKR). For the composite primary outcome of any deep vein thrombosis (DVT), non-fatal pulmonary embolism (PE) and death from all causes the relative risk reductions were 70-79% in THR and 31-49% in TKR. Rivaroxaban also had superior efficacy over enoxaparin for the secondary outcome major VTE. Rivaroxaban was not inferior to enoxaparin on the safety outcome of major bleeding. After the correction of some errors found by the ERG, the manufacturer's economic model represented a reasonable model of patients receiving prophylaxis for THR or TKR. In the base-case analyses rivaroxaban dominated both enoxaparin and dabigatran. The incremental costs saved and quality-adjusted life-years (QALYs) gained were small (below 200 pounds and 0.005, respectively, per person). Analyses were conducted sampling from the distributions observed from the RCTs. When all parameters were sampled rivaroxaban dominated enoxaparin in all scenarios except for two, in which enoxaparin produced more QALYs than rivaroxaban and had an incremental cost per QALY gained of 5000 pounds and 8000 pounds respectively. Rivaroxaban dominated dabigatran when RECORD 1 and RECORD 2, individually or pooled, were compared with RE-NOVATE and when all four rivaroxaban RCTs pooled were compared with all three dabigatran RCTs. Dabigatran dominated rivaroxaban comparing RECORD 4 with RE-MODEL and RE-MOBILIZE, and was more cost-effective than rivaroxaban comparing RECORD 3 (incremental cost per QALY gained of rivaroxaban compared with dabigatran of 123,000 pounds) or RECORD 3 and RECORD 4 pooled (incremental cost per QALY gained of dabigatran compared with rivaroxaban of 400 pounds) with RE-MODEL and RE-MOBILIZE. In conclusion, the evidence indicates that rivaroxaban is not inferior to enoxaparin in terms of the primary and secondary outcomes. The submission presents a reasonable estimation of the cost-effectiveness of rivaroxaban compared with enoxaparin and dabigatran, although the uncertainty in the decision has been underestimated. The results are particularly sensitive to any assumed difference in the number of fatal PEs, but the ERG does not believe there is sufficient evidence to support a difference between interventions. The NICE guidance issued as a result of the STA states that: riveroxaban, within its marketing authorisation, is recommended as an option for the prevention of venous thromboembolism in adults having elective THR or elective TKB.
Collapse
Affiliation(s)
- M Stevenson
- School of Health and Related Research, University of Sheffield, UK.
| | | | | | | | | |
Collapse
|
43
|
Ara R, Pandor A, Stevens J, Rees A, Rafia R. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation. Health Technol Assess 2009; 13:1-74, 75-118. [PMID: 19604457 DOI: 10.3310/hta13340] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
OBJECTIVE To evaluate the cost-effectiveness of high-dose statins (atorvastatin 80 mg/day, rosuvastatin 40 mg/day and simvastatin 80 mg/day) versus simvastatin 40 mg/day in individuals with acute coronary syndrome (ACS). DATA SOURCES Eleven bibliographic databases, including MEDLINE, CINAHL, EMBASE, Cochrane Database of Systematic Reviews, CENTRAL, DARE and NHS EED, were searched from inception to 2008. REVIEW METHODS Data relating to study design, baseline patient characteristics, clinical or surrogate outcome, and adverse events were abstracted, and methodological quality was assessed according to standard methods. A synthesis of the available evidence was performed using a Bayesian mixed treatment meta-analysis using both direct and indirect evidence. An existing Markov model was modified to explore the costs and benefits associated with a lifetime of the differing treatment regimens. RESULTS A total of 3345 titles and abstracts were screened for inclusion in the review of clinical effectiveness and 125 full papers retrieved and assessed in detail. Of these, 30 papers met the inclusion criteria for the review, describing 28 trials. The Bayesian mixed treatment meta-analysis demonstrated a clear dose-response relationship in terms of reductions in low-density lipoprotein cholesterol (LDL-c), with rosuvastatin 40 mg/day achieving the greatest percentage reduction (56%) from baseline, followed by atorvastatin 80 mg/day (52%), simvastatin 80 mg/day (45%) and simvastatin 40 mg/day (37%). Although serious adverse events with statins are rare, their incidence is likely to be greater with higher doses. Several clinical scenarios were used to explore the effect of adherence on the cost-effectiveness of the treatment regimens. Using a threshold of 20,000 pounds per quality-adjusted life-year (QALY) and assuming that the benefits and adherence rates observed in the clinical trials are generalisable to a clinical setting and that individuals who do not tolerate the higher-dose statins are prescribed simvastatin 40 mg/day, then simvastatin 80 mg/day, atorvastatin 80 mg/day and rosuvastatin 40 mg/day would be considered cost-effective compared with simvastatin 40 mg/day in individuals with ACS. Simvastatin 80 mg/day is not well tolerated because of the high incidence rates of less severe adverse events such as myopathy (26-fold higher than rates in those receiving simvastatin 20 mg/day), which are likely to affect adherence levels in clinical practice. The reference case shows that rosuvastatin is the optimal treatment for individuals with a recent history of ACS using a threshold of 20,000 pounds per QALY. However, this is based on the assumption that the additional incremental reductions in LDL-c observed in patients treated with rosuvastatin 40 mg/day compared with atorvastatin will transfer into corresponding changes in relative risks of cardiovascular events. CONCLUSIONS Simvastatin 80 mg/day cannot be recommended because of the high incidence rates of adverse events. If the cost of atorvastatin decreases in line with that observed for simvastatin when the patent ends in 2011, atorvastatin 80 mg/day will be the most cost-effective treatment for all thresholds; if the cost reduces to 25% of the current value, atorvastatin 80 mg/day will be the most cost-effective treatment for thresholds between 5000 pounds and 30,000 pounds per QALY. Large long-term RCTs reporting effects in terms of clinical events are required to determine the optimum statin use for subgroups.
Collapse
Affiliation(s)
- R Ara
- The University of Sheffield, School of Health and Related Research, UK
| | | | | | | | | |
Collapse
|
44
|
|
45
|
Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technol Assess 2009. [DOI: 10.3310/hta13suppl3-07] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of rivaroxaban for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery based upon a review of the manufacturer’s submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The submission’s evidence came from four randomised controlled trials (RCTs) comparing rivaroxaban with enoxaparin [RECORD (Regulation of Coagulation in Orthopedic surgery to pRevent Deep venous thrombosis and pulmonary embolism) 1–4] and three comparing dabigatran with enoxaparin [RE-NOVATE (the prevention of venous thromboembolism after total hip replacement trial), RE-MODEL (the prevention of venous thromboembolism after total knee replacement trial) and RE-MOBILIZE (the prevention of venous thromboembolism after total knee arthroplasty trial)]. The evidence from the four RECORD trials indicates that rivaroxaban had superior efficacy over enoxaparin after total hip replacement (THR) and total knee replacement (TKR). For the composite primary outcome of any deep vein thrombosis (DVT), non-fatal pulmonary embolism (PE) and death from all causes the relative risk reductions were 70–79% in THR and 31–49% in TKR. Rivaroxaban also had superior efficacy over enoxaparin for the secondary outcome major VTE. Rivaroxaban was not inferior to enoxaparin on the safety outcome of major bleeding. After the correction of some errors found by the ERG, the manufacturer’s economic model represented a reasonable model of patients receiving prophylaxis for THR or TKR. In the base-case analyses rivaroxaban dominated both enoxaparin and dabigatran. The incremental costs saved and quality-adjusted life-years (QALYs) gained were small (below £200 and 0.005, respectively, per person). Analyses were conducted sampling from the distributions observed from the RCTs. When all parameters were sampled rivaroxaban dominated enoxaparin in all scenarios except for two, in which enoxaparin produced more QALYs than rivaroxaban and had an incremental cost per QALY gained of £5000 and £8000 respectively. Rivaroxaban dominated dabigatran when RECORD 1 and RECORD 2, individually or pooled, were compared with RE-NOVATE and when all four rivaroxaban RCTs pooled were compared with all three dabigatran RCTs. Dabigatran dominated rivaroxaban comparing RECORD 4 with RE-MODEL and RE-MOBILIZE, and was more cost-effective than rivaroxaban comparing RECORD 3 (incremental cost per QALY gained of rivaroxaban compared with dabigatran of £123,000) or RECORD 3 and RECORD 4 pooled (incremental cost per QALY gained of dabigatran compared with rivaroxaban of £400) with RE-MODEL and RE-MOBILIZE. In conclusion, the evidence indicates that rivaroxaban is not inferior to enoxaparin in terms of the primary and secondary outcomes. The submission presents a reasonable estimation of the cost-effectiveness of rivaroxaban compared with enoxaparin and dabigatran, although the uncertainty in the decision has been underestimated. The results are particularly sensitive to any assumed difference in the number of fatal PEs, but the ERG does not believe there is sufficient evidence to support a difference between interventions. The NICE guidance issued as a result of the STA states that: riveroxaban, within its marketing authorisation, is recommended as an option for the prevention of venous thromboembolism in adults having elective THR or elective TKB.
Collapse
Affiliation(s)
- M Stevenson
- School of Health and Related Research (ScHARR), University of Sheffield, UK
| | - A Scope
- School of Health and Related Research (ScHARR), University of Sheffield, UK
| | - M Holmes
- School of Health and Related Research (ScHARR), University of Sheffield, UK
| | - A Rees
- School of Health and Related Research (ScHARR), University of Sheffield, UK
| | - E Kaltenthaler
- School of Health and Related Research (ScHARR), University of Sheffield, UK
| |
Collapse
|
46
|
Hunnings E, Rees A. Helene Julia Mair. West J Med 2009. [DOI: 10.1136/bmj.b3931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
47
|
Pilgrim H, Lloyd-Jones M, Rees A. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation. Health Technol Assess 2009; 13:iii, ix-xi, 1-103. [PMID: 19210896 DOI: 10.3310/hta13100] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
OBJECTIVES To identify any evidence for advances in the use of routine antenatal anti-D prophylaxis (RAADP) since the 2002 National Institute for Health and Clinical Excellence (NICE) appraisal, and to assess the current clinical effectiveness and cost-effectiveness of RAADP for Rhesus D (RhD)-negative women. DATA SOURCES Main bibliographic databases were searched from inception to July 2007. REVIEW METHODS Selected studies were assessed and data extracted using a standard template and quality assessment based on published criteria. Meta-analysis was used where appropriate, otherwise outcomes were tabulated and discussed within a descriptive synthesis. The health economic model developed for the 2002 NICE appraisal of RAADP was modified to assess the cost-effectiveness of different regimens of RAADP. RESULTS The clinical effectiveness searches identified 670 potentially relevant articles. Of these, 12 papers were included in the review, relating to eight studies of clinical effectiveness. With one exception, no additional studies were identified in comparison with the previous assessment report, and some of the studies of clinical effectiveness included in the 2002 review had to be excluded because they did not use currently licensed doses. Therefore, eight studies comparing RAADP with no prophylaxis were identified in the clinical effectiveness review and nine (including the 2001 assessment report itself) in the cost-effectiveness review. The clinical efficacy studies were generally of poor quality and did not provide a basis for differentiating between regimens of RAADP. The best indication of the likely efficacy of a programme of RAADP comes from two non-randomised community-based studies. The pooled results of these suggest that such a programme may reduce the sensitisation rate from 0.95% (95% CI 0.18-1.71) to 0.35% (95% CI 0.29-0.40). This gives an odds ratio for the risk of sensitisation of 0.37 (95% CI 0.21-0.65) and an absolute reduction in risk of sensitisation in RhD-negative mothers at risk (i.e. carrying a RhD-positive child) of 0.6%. The identified studies suggest that RAADP has minimal adverse effects. Of the nine studies in the cost-effectiveness review, only two described a model that could be applicable to the NHS. The economic model modified from the 2002 appraisal suggests that the cost per quality-adjusted life-year (QALY) gained of RAADP given to RhD-negative primigravidae versus no treatment is between 9000 pounds and 15,000 pounds, and for RAADP given to all RhD-negative women rather than to RhD-negative primigravidae only is between 20,000 pounds and 35,000 pounds depending upon the regimen. The sensitivity analysis suggests that the results are reasonably robust to changes in the assumptions within the model. CONCLUSIONS RAADP reduces the incidence of sensitisation and hence of haemolytic disease of the newborn. The economic model suggests that RAADP given to all RhD-negative pregnant women is likely to be cost-effective at a threshold of around 30,000 pounds per QALY gained. The total cost of providing RAADP to RhD-negative primigravidae in England and Wales is estimated to be around 1.8-3.1 million pounds per year, depending upon regimen, and to all RhD-negative pregnant women in England and Wales around 2-3.5 million pounds.
Collapse
Affiliation(s)
- H Pilgrim
- The University of Sheffield, School of Health and Related Research, UK
| | | | | |
Collapse
|
48
|
Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R, Nicholson K. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technol Assess 2009; 13:iii, ix-xii, 1-246. [PMID: 19215705 DOI: 10.3310/hta13110] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
OBJECTIVES To evaluate the clinical effectiveness and incremental cost-effectiveness of amantadine, oseltamivir and zanamivir for seasonal and post-exposure prophylaxis of influenza. DATA SOURCES A MEDLINE search strategy was used and searches were carried out in July 2007. REVIEW METHODS An independent health economic model was developed based on a review of existing cost-effectiveness models and clinical advice.The model draws together a broad spectrum of evidence relating to the costs and consequences associated with influenza and its prevention. Where direct evidence concerning the effectiveness of prophylaxis within specific model subgroups was lacking, the model uses estimates from mixed subgroups or extrapolates from other mutually exclusive subgroups. RESULTS Twenty-six published references relating to 22 randomised controlled trials (RCTs) were included in the clinical effectiveness review, along with one unpublished report. Eight, six and nine RCTs were included for amantadine, oseltamivir and zanamivir respectively. The study quality was variable and gaps in the evidence base limited the assessment of the clinical effectiveness of the interventions. For seasonal prophylaxis, there was limited evidence for the efficacy of amantadine in preventing symptomatic, laboratory-confirmed influenza (SLCI) in healthy adults [relative risk (RR) 0.40, 95% confidence interval (CI) 0.08-2.03]. Oseltamivir was effective in preventing SLCI, particularly when used in at-risk elderly subjects (RR 0.08, 95% CI 0.01-0.63). The preventative efficacy of zanamivir was most notable in at-risk adults and adolescents (RR 0.17, 95% CI 0.07-0.44), and healthy and at-risk elderly subjects (RR 0.20, 95% CI 0.02-1.72). For post-exposure prophylaxis, data on the use of amantadine were again limited: in adolescents an RR of 0.10 (95% CI 0.03-0.34) was reported for the prevention of SLCI. Oseltamivir was effective in households of mixed composition (RR 0.19, 95% CI 0.08-0.45). The efficacy of zanamivir in post-exposure prophylaxis within households was also reported (RR 0.21, 95% CI 0.13-0.33). Interventions appeared to be well tolerated. Limited evidence was available for the effectiveness of the interventions in preventing complications and hospitalisation and in minimising length of illness and time to return to normal activities. No clinical effectiveness data were identified for health-related quality of life or mortality outcomes. With the exception of at-risk children, the incremental cost-utility of seasonal influenza prophylaxis is expected to be in the range 38,000-428,000 pounds per QALY gained (depending on subgroup). The cost-effectiveness ratios for oseltamivir and zanamivir as post-exposure prophylaxis are expected to be below 30,000 pounds per QALY gained in healthy children, at-risk children, healthy elderly and at-risk elderly individuals. Despite favourable clinical efficacy estimates, the incorporation of recent evidence of viral resistance to amantadine led to it being dominated in every economic comparison. CONCLUSIONS All three interventions showed some efficacy for seasonal and post-exposure prophylaxis. However, weaknesses and gaps in the clinical evidence base are directly relevant to the interpretation of the health economic model and rendered the use of advanced statistical analyses inappropriate. These data limitations should be borne in mind in interpreting the findings of the review.
Collapse
Affiliation(s)
- P Tappenden
- University of Sheffield, School of Health and Related Research, UK
| | | | | | | | | | | | | |
Collapse
|
49
|
Rees A, Stocks J, Schoulders C, Carlson LA, Baralle FE, Galton DJ. Restriction enzyme analysis of the apolipoprotein A-I gene in fish eye disease and Tangier disease. Acta Med Scand 2009; 215:235-7. [PMID: 6428166 DOI: 10.1111/j.0954-6820.1984.tb05000.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Restriction enzyme analysis of the apolipoprotein A-I (apo A-I) gene was performed in two patients with fish eye disease and one with Tangier disease. Despite the marked deficiency of high density lipoprotein and concomitantly of apo A-I in these two conditions, no evidence was found for major deletions or insertions in the apo A-I gene.
Collapse
|
50
|
Sutcliffe P, Hummel S, Simpson E, Young T, Rees A, Wilkinson A, Hamdy F, Clarke N, Staffurth J. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technol Assess 2009; 13:iii-iv, ix-xii, 1-315. [PMID: 19128541 DOI: 10.3310/hta13050] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
OBJECTIVES To provide an evidence-based perspective on the prognostic value of novel markers in localised prostate cancer and to identify the best prognostic model including the three classical markers and investigate whether models incorporating novel markers are better. DATA SOURCES Eight electronic bibliographic databases were searched during March-April 2007. The reference lists of relevant articles were checked and various health services research-related resources consulted via the internet. The search was restricted to publications from 1970 onwards in the English language. METHODS Selected studies were assessed, data extracted using a standard template, and quality assessed using an adaptation of published criteria. Because of the heterogeneity regarding populations, outcomes and study type, meta-analyses were not undertaken and the results are presented in tabulated format with a narrative synthesis of the results. RESULTS In total 30 papers met the inclusion criteria, of which 28 reported on prognostic novel markers and five on prognostic models. A total of 21 novel markers were identified from the 28 novel marker studies. There was considerable variability in the results reported, the quality of the studies was generally poor and there was a shortage of studies in some categories. The marker with the strongest evidence for its prognostic significance was prostate-specific antigen (PSA) velocity (or doubling time). There was a particularly strong association between PSA velocity and prostate cancer death in both clinical and pathological models. In the clinical model the hazard ratio for death from prostate cancer was 9.8 (95% CI 2.8-34.3, p < 0.001) in men with an annual PSA velocity of more than 2 ng/ml versus an annual PSA velocity of 2 ng/ml or less; similarly, the hazard ratio was 12.8 (95% CI 3.7-43.7, p < 0.001) in the pathological model. The quality of the prognostic model studies was adequate and overall better than the quality of the prognostic marker studies. Two issues were poorly dealt with in most or all of the prognostic model studies: inclusion of established markers and consideration of the possible biases from study attrition. Given the heterogeneity of the models, they cannot be considered comparable. Only two models did not include a novel marker, and one of these included several demographic and co-morbidity variables to predict all-cause mortality. Only two models reported a measure of model performance, the C-statistic, and for neither was it calculated in an external data set. It was not possible to assess whether the models that included novel markers performed better than those without. CONCLUSIONS This review highlighted the poor quality and heterogeneity of studies, which render much of the results inconclusive. It also pinpointed the small proportion of models reported in the literature that are based on patient cohorts with a mean or median follow-up of at least 5 years, thus making long-term predictions unreliable. PSA velocity, however, stood out in terms of the strength of the evidence supporting its prognostic value and the relatively high hazard ratios. There is great interest in PSA velocity as a monitoring tool for active surveillance but there is as yet no consensus on how it should be used and, in particular, what threshold should indicate the need for radical treatment.
Collapse
Affiliation(s)
- P Sutcliffe
- The University of Sheffield, School of Health and Related Research (ScHARR), UK
| | | | | | | | | | | | | | | | | |
Collapse
|